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                                                                  Introduction:
Duchenne  Muscular  dystrophy  (DMD) is  one  of  the  commonest  forms  of  muscular 
dystrophy and is a devastating neuromuscular disorder with relentless progression. It 
starts  in  childhood  with  delayed  milestones,  abnormal  gait,  frequent  falls,  and 
difficulties in climbing stairs and rising from squatting position, contractures and calf 
muscles enlargement. About a third of them have IQ below 70. Over a period of time, 
there is progressive decline in muscle strength with loss of ambulation at a mean age of 
9.5  years.  Other  features  include  respiratory  insufficiency,  scoliosis  and 
cardiomyopathy.  Eventually,  death  occurs  from  respiratory  insufficiency  or  cardiac 
causes at a mean age of 19 years. The diagnosis is based on clinical features, raised 
serum Creatine  phosphokinase  (CPK),  absence  of  dystrophin  in  muscle  biopsy  and 
finding of mutation in dystrophin gene. Treatment goals are to maintain ambulation as 
long as possible, prevent contractures, and provide psychological support. These can be 
achieved  with  physiotherapy,  bracing,  surgical  correction  of  scoliosis  and 
corticosteroids. Other treatments aiming at the correction of the gene defect itself are not 
yet available for clinical use.
 Problems with diagnosis and management
 DMD is a common inherited disorder but still can have diagnostic problems, especially 
in  terms  of  timing  of  the  diagnosis  as  early  features  of  developmental  delay  and 
clumsiness  while  walking  may  be  not  be  recognised  as  a  manifestation  of  disease 
process. An early diagnosis and initiation of treatment are important, considering the 
beneficial effects of steroids and inflammatory changes seen in early part of the disease. 
Gene based test are helpful but may be negative in some patients with smaller mutations 
and at uncommon sites, they may also not distinguish between those with various levels 
of protein deficiency. Muscle biopsy with immunohistochemistry for loss of dystrophin 
remains the gold standard for diagnosis, characterisation and prognostication. Treatment 
options are limited with corticosteroids and physiotherapy showing benefit in prolonging 
the  duration of  ambulation  with additional  beneficial  effects  on cardiac  functioning. 
Other drugs are tried with variable results but none with proven effect on survival or 
cure potential. Gene therapy has been tried but with limited success due to the large size 
of  dystrophin  gene,  problems  with  finding  suitable  vectors  for  transportation  of  the 
products,  and  other  related  problems.  At  present,  corticosteroids  with  physiotherapy 
remains  the  cornerstone  of  treatment,  and  in  addition,  management  of  scoliosis, 
contractures,  cardiac and respiratory illness,  until  newer modalities  of  treatment  like 
stem cell  therapy  using  myogenic  precursors  with  capability  of  reaching  the  target 
muscles by systemic delivery are found feasible and translated into DMD patients.
There  are  few  studies  aimed  at  describing  the  clinical  profile,  natural  history, 
progression  of  the  disease  over  a  period  of  time and the  effect  of  multidisciplinary 
therapy, which includes both drug and non pharmacological 
methods,  including  Physiotherapy  and  Occupational  therapy  on  children  with  this 
devastating disorder.     
The purpose of  this  study was to look at  the natural  history of  a  cohort  of  patients 
attending  a  comprehensive  multidisciplinary  clinic  dedicated  to  the  management  of 
neuromuscular disorders. The patients with DMD are seen
in the clinic and a comprehensive assessment by made by the Neurologist, Physiatrist, 
Occupational and Physiotherapist and a Clinical Geneticist, where the initial work up 
including muscle biopsy is planned. After ascertaining the diagnosis, treatment options 
including pharmacological measures and non pharmacological measures like endurance 
enhancing  and  stretching  exercises  and  advice  on  need  based  ADL’s.  Genetic 
counselling is done by the Clinical geneticist. These patients get followed up once every 
6 months.   
This  study looks at  the entire  aspect  of  clinical  profile  including the  developmental 
aspects,  early  symptomatology  and  a  chronological  record  of  various  stages  of  the 
disease and this is correlated with the genetic aspects,
Histopathological  data,  treatment  options,  both  pharmacological  and  non 
pharmacological, using a structured proforma.  The natural history is obtained from both 
the treated group and historical controls seen in the clinic.
Aims of the study: 
To study the natural history, the rate of progression of disease in patients with Duchenne 
Muscular dystrophy and the impact of treatment on outcome measures.
Objectives of the study:
1.  To  study  the  disease  related  milestones  including  time  to  stop  ambulation  and 
confinement  to  wheel  chair  during  the  course  of  illness  in  Duchenne  muscular 
dystrophy.
2. To assess the muscle power and functional measures, anthropometric and goniometric 
changes and correlate these measures with the various activities of daily living using 
validated assessment scores.
3. To compare the outcome measure of  time to  stop ambulation in  patients  who 
received  the  comprehensive  treatment  for  at  least  2  years  with  the  historical 
controls.
4.
Review of literature:     
Dystrophinopathies include a spectrum of X linked recessive muscle diseases 
caused  by  mutations  in  DMD  gene.  The  milder  forms  are  asymptomatic 
increase in serum creatine kinase and muscle cramps with myoglobinuria and 
isolated  quadriceps  myopathy.  The  severe  forms  are  Duchenne/Becker’s 
muscular  dystrophy  (DMD/BMD)  and  DMD  -  associated  dilated 
cardiomyopathy when the heart is primarily affected. 
Historical aspects of Dystrophinopathies     
Edward Meryon (1852) and John Little (1853) described families with delayed 
motor milestones, calf enlargement, progressive inability to walk, contractures 
and death at an early age. G.B.A Duchenne (1868) gave the diagnostic criteria 
which include weakness and hypertrophy of  muscles  with onset  in  the legs, 
hyperlordosis with wide-based gait, progressive course over time and absence 
of bladder or bowel dysfunction or sensory disturbance.
William Gowers deduced the genetic basis for the disease. Lindenbaum R H 
(1979) and Davies K E (1983) revealed mutation in the specific Xp21 position 
in patients with DMD and BMD. The defective gene was identified by Monaco 
A P.   Peter  E Becker  proposed that  the  less  symptomatic  patients  reflected 
milder mutations in the same gene.  Kunkel L M (1986) identified the DMD 
gene located at band Xp21 and provided molecular genetic confirmation of X-
linked inheritance pattern.1, 2, 3                                                                                                                              
Incidence and prevalence: 
DMD is the most common childhood onset muscular dystrophy. It affects 1 in 
3500 boys, with an overall incidence of 25:100,000 live male births per year 
and prevalence of 63 cases per million. Approximately 50 % of muscle diseases 
in India are Duchenne Muscular dystrophies. 3, 4, 5               
Sex distribution:                                                                                            
DMD almost exclusively affect males because of X-linked inheritance. Rarely, 
skewed random inactivation of healthy copies of X chromosome causes Becker 
phenotype  in  females.  Females  with  Turner  syndrome  (XO)  or  uniparental 
disomy or those with translocations between the X and autosomal chromosomes 
may similarly manifest the Duchenne phenotype.
Age group:                                                                                                      
DMD clinically  manifests  in  3  -  7  years  age  group.  Mean age at  diagnosis 
without family history is 4 years, 10 months (range - 16 months to 8 years).6        
 Genetics: 
DMD is caused by mutations in the  DMD gene localized to short arm of X 
chromosome which encodes for dystrophin protein.4                                
DMD gene: 
It is one of the largest known genes (0.1% of the human genome and 2.3 mega 
bases).  It contains 79 exons (0.6% of the gene) and large introns (99.4% of the 
gene).  Its large size makes it susceptible to mutations, with one third of all 
mutations arising de novo.7, 8, 9, 
DMD gene mutations and disease/ co-relation: 
One  third  of  cases  are  due  to  spontaneous  mutations,  rest  have  X  linked 
inheritance. Gonadal mosaicism accounts for approximately 20% cases.         
Majority  of  mutations  are  intra-genic  deletions  (65-72%)  in  the  hotspot 
spanning  exons  45-53, with  most  being  deletions  of  exon  45,  and  45-47. 
Duplications are found in 7% of patients, mostly in a minor hotspot spanning 
exons 2-20.  20% cases have point mutations, small deletions or insertions. Most 
of the mutations are nonsense, frame shift or splice site mutations. Mutations 
lead to loss of the reading frame, resulting in a severe reduction or complete 
absence of dystrophin protein. Size and position of the deletion often does not 
correlate with the phenotype. Mutations that disrupt the open reading frame, 
resulting in  an abnormal/  truncated dystrophin cause DMD, while mutations 
maintaining the open reading frame, resulting in a shorter and partly functional 
protein cause BMD (reading frame rule). 90% of the cases of DMD and BMD 
conform to this rule. 10, 11, 12, 13, 14
Dystrophin protein: 
It is a 3685 amino acid, 427kDa cytoskeleton protein and member of β spectrin/ 
α actinin family. It is expressed in Skeletal, Cardiac & Smooth Muscles. Brain 
has B isoform which is functionally homologous to muscle isoform. It localizes 
to cytoplasmic face of sarcolemma, as a component of dystrophin associated 
glycoprotein complex (DGC). It consists of an N-terminal actin binding domain, 
24 spectrin like repeat units, interspersed by four hinge regions, followed by a 
cysteine  rich  and  a  C  terminal  domain. The  cysteine  rich  domain  binds  to 
laminin 2 via alpha and beta dystroglycan, acting as mechanical link between 
actin in the cytoskeleton, and the extracellular matrix (Figures 1 and 2).13, 15, 16  
Functions of dystrophin protein: 
 Role in stabilization of muscle membrane during contraction
 Part of link between intracellular cytoskeleton & extra cellular matrix, essential for 
force transduction. 
Proposed mechanisms of disease pathogenesis: 
Absence of dystrophin at the plasma membrane leads to 
 Delocalization  of  dystrophin  associated  proteins  from  the  membrane, 
disruption  of  cytoskeleton  with  resultant  membrane  instability  and 
increased susceptibility to mechanical stress (possible role of dystrophin 
in resealing mechanisms). 
 Altered  membrane  permeability  and  abnormal  calcium  homeostasis 
leading to activation of proteases such as calpain. 
 Oxidative damage and apoptosis.
 Inflammatory response mediated by mast cells and dendritic cells. 
 Absence  of  NO  synthase  at  the  subsarcolemmal  membrane  causes 
functional ischemia in areas of muscle during exercise. 13,17,18
These lead to muscle fiber degeneration, initially there is regeneration of muscle 
fibers which with disease progression in overwhelmed with replacement of lost 
muscle fibers with fibro fatty tissue. Absence of dystrophin secondarily affects 
the synthesis of the Dystrophin associated proteins, which are reduced by 90%. 
Therefore,  in  DMD,  functional  deficits  are  the  result  of  the  absence  of 
dystrophin and deficiency of Dystrophin associated proteins.14
Animal models of DMD with mutation in DMD gene:
Commonly studied,  preferred and used is the  mdx mouse. Several strains of 
mdx mouse have been characterized. Other models include hypertrophic feline 
muscular dystrophy and canine X linked muscular dystrophy models (golden 
retriever  muscular  dystrophy  dog and German  short  haired  pointer).  Canine 
models are better phenocopies of human disease than other animal models, but 
limited by short lifespan, problems with breeding and cost.19                                                       
                                                                                                                                                                                                       
Clinical features:
DMD presents with progressive weakness in limbs since childhood. 
Affected children are normal at birth, later they are noted to have delayed motor milestones. 
Mean age of by which, walking is attained is around 18 months (range 12-24 months). When 
the boys  begin walking,  the clumsiness seen in all  toddlers persists.  Within 2 to 3 years 
children are noted to have abnormal wide based gait with waddling/toe walking, inability to 
run  compared  to  their  peers  and  climb  stairs,  difficulty  to  squat  and  getup  with  use  of 
Gower’s maneuver to do so.  A frequent complaint from parents of affected, 4 to 5 year old 
boys is that their son is unable to keep up with his peers in athletic endeavors.  Standing 
posture is  abnormal  with increased lumbar  lardosis  and wide stance to  increase stability. 
Often,  at  this  stage  the  calf  muscles  are  enlarged  and  rubbery  on  palpation  (pseudo 
hypertrophy) due to fatty and fibrotic infiltration of necrotic muscles. Another explanation is 
compensatory hypertrophy of the secondary to weak tibialis anterior muscles, which tend to 
be  more  affected.  Hypertrophy may become generalized  and usually  increases  with  age. 
Some relatively spared  muscles  may have  true  hypertrophy.  By 5  or  6  years  they  have 
laboured stair climbing and moving upward requires support of the bannister.  At around 6 or 
7 years, they start having spontaneous falls due to abrupt knee buckling.   At about 8 to12 
years, there is severe deterioration in functional capabilities, as they cannot climb stairs or 
stand up from the floor. They stop walking by 9 -13 years and begin using a wheelchair by a 
mean age of 9.5 years.  The respiratory muscle strength begins to decline at around a mean 
age of 8 years. 
Generally,  proximal  muscles  of  the lower  limbs are  the first  to  be involved 
followed  by  proximal  upper  limb  muscles.  Neck  flexors,  wrist  extensors, 
quadriceps, tibialis anterior, biceps, and triceps muscles are affected more than 
the neck extensors, wrist flexors, deltoids, hamstrings, gastrocnemii, and solei. 
Ankle plantar flexors and invertors are remarkably spared throughout the course 
of  illness.  Cranial  musculature  is  usually  spared.  Infraspinatus  and  deltoid 
muscles are enlarged and between them, muscles forming the posterior axillary 
fold are wasted (Valley sign). Deep tendon reflexes tend to parallel muscle fiber 
loss, slowly diminish and ultimately disappear. 3, 4, 6, 13, 14, 20
Contractures at the iliotibial bands, hip joints, and ankle joints are seen in most 
patients by 6 years of age. Limitation of knee, elbow and wrist extension occur 
around 8 years of age, while shoulders are spared until late into disease.  By 10 
years, 70% of children are disabled by contractures, hips and knees lock at 90° 
and the feet are in an exaggerated equinovarus position. Asymmetric weakening 
of  paraspinal  muscles  causes  kyphoscoliosis,  usually  appearing  after  loss  of 
ambulation.  
Progressive  respiratory  impairment  with  weak  cough  causes  atelectasis  with 
recurrent  episodes  of  pneumonia.  Most  have  progressive  dilated 
cardiomyopathy.   Patients  develop  terminal  respiratory  or  cardiac  failure, 
usually by the late teens or early 20 years of age. Life expectancy is prolonged 
by 6 to 25 years with respiratory support. 3, 4, 6, 13, 14, 20 
The  Outlier’s  comprise  around  15%  of  the  Dystrophinopathies,  otherwise 
fulfilling  the  criteria  for  DMD,  but  have  milder  progression.  They  have 
relatively preserved neck flexors.  They are able to climb stairs without support 
at 8 years and at 12 years of age still can climb stairs with support from railing. 
Forced vital capacity is usually 90% of predicted. 20
BMD  has  a  later  onset  of  skeletal  muscle  weakness  with  patients’  being 
ambulatory  even  in  their  20’s.  Pattern  of  weakness  and  wasting  closely 
resembles  DMD.  Muscles  of  the  pelvic  girdle  and  thighs  are  prominently 
involved  with  relatively  less  involvement  of  anterior  tibial  and  peroneal 
muscles. Neck flexor weakness appears late into illness. Forearm muscles, hand 
muscles and ankle plantar flexors are relatively preserved until late into illness. 
Significant  facial  weakness  is  generally  not  a  feature  of  BMD.   Calf 
hypertrophy is early and almost an universal feature. Contractures and scoliosis 
are not as prominent as in DMD and ambulation is never lost before 16 years of 
age. Despite the milder skeletal muscle involvement, heart failure from DCM is 
a common cause of morbidity and death. Cognitive impairment is not common/ 
severe as in DMD and the mean age of death is around the fifth decade.  
Mild end of the spectrum includes men with onset of symptoms after age 30 
years, who remain ambulatory even into the sixth decade. Other forms are BMD 
with  subclinical  skeletal  muscle  involvement,  elevated  serum  CPK,  calf 
hypertrophy, cramps, myalgia, and exertional myoglobinuria. 20
DMD and Cardiac disease: Cardiomyopathy and Arrhythmias
Incidence of cardiomyopathy increases steadily in teenage years, with 1/3 being 
affected by 14 years, ½ by 16 years and all patients’ after18 years of age. It is 
commonly  dilated  cardiomyopathy  (DCM),  can  also  be  hypertrophic  form. 
Preclinical cardiac involvement is seen in 25% of patients  < 6 years of age, 
commonly  with  a  persistent  tachycardia. Despite  the  high  frequency  of 
cardiomyopathy,  most  patients  are  relatively  asymptomatic  due  to  physical 
inactivity. Dystrophin  deficient  cardiomyocytes  have  reduced  threshold 
sarcolemmal  injury under mechanical  stress.  Cellular  repair  mechanisms and 
regeneration  are  insufficient,  leading  to  progressive  loss  of  cardiomyocytes. 
Characteristic cardiac lesion is focal necrosis with mononuclear infiltrate. Focal 
involvement  may  appear  as  wall  motion defects  with  a  predilection  for 
posterobasal  and  posterolateral segments  of  the  left  ventricular  wall  due  to 
fibrosis in these areas. These areas are referred to as micro infarcts and may 
have associated chest pain and release of troponin. There is relative sparing of 
the interventricular septum, and comparatively minimal involvement of the right 
ventricle  and  atrial  myocardium.  Degenerative  changes  also  involve  the 
conducting system.   Finally four chamber dilation and failure occurs. 
Electrocardiogram   changes often appear in the late first decade, including sinus 
tachycardia, tall R wave in lead V1, and inferolateral Q waves. Echocardiogram 
shows valve motion, wall thickness and motion abnormalities. Tissue Doppler 
can  identify  myopathic  changes earlier,  reflecting  ongoing  damage  to 
myocardium. Magnetic resonance imaging is sensitive in detecting subclinical 
disease.  
Conduction/rhythm disturbances include Sinus node dysfunction, AV node 
dysfunction,  atrial fibrillation  and  ventricular  tachycardia/fibrillation.  They 
increase in frequency as ventricular dysfunction progresses. 
Selective Cardiomyopathy                                                                  
Some males can have minimal or mild weakness with DCM.  Onset is in late 
teens  with  rapidly  progressive  congestive  heart  failure  over  1  to  2  years. 
Manifesting  female  carriers  with  DCM  have  onset  in  5th  decade  with 
congestive heart failure and atypical chest pain. They have slowly progressive 
disease over more than 10 years. 13, 20, 21, 22, 23
Orthopedic complications
Scoliosis develops in almost all, and impairs the vital capacity. It progresses 
significantly after boys lose ambulation, and maintenance of ambulation slows 
the rate of progression. Long bone fractures usually due to falls are common, 
affecting 21-44% of boys. Half of them occur in independently ambulant boys, 
with 20-40% losing ambulation as a result. Osteoporosis is present in most 
patients. Loss of bone mineral density begins even when boys are still ambulant, 
and continues to diminish with age.13, 24
Malignant hyperthermia
DMD patients are thought to have risk of malignant hyperthermia like reactions 
if exposed to anesthetics such as halothane or succinylcholine.25
 
Respiratory complications
Respiratory insufficiency due to restrictive lung disease is common. The vital 
capacity decreases at a rate of 8 -12% per year, after 10 years of age. When it 
reaches less  than one Litre,  the risk of  death within the next  1 -  2 years is 
relatively high. Obstructive sleep apnea causes sleep disordered breathing in the 
first decade in up to one third of patients, with hypoventilation occurring in the 
second decade. 13, 26, 27                                                                                                                                                  
Brain and dystrophinopathy:
A nonprogressive intellectual  disability  and hyperactivity  are seen in around 
30% of patients with DMD. These features are due to deficiency of the brain 
isoform of dystrophin.  Brain may show cortical  atrophy with neuronal  loss, 
heterotopias, gliosis,  neurofibrillary  tangles,  dendritic abnormalities  and 
disordered architecture.  
A. Specific cognitive profile associated with DMD.                                       
IQ is shifted 1 SD lower than normal (average 85). 30% of boys have IQ of < 70 
with about 19% of them in the mentally retarded range. They do well on written 
memory, long term memory tests and visuospatial skills. They perform poorly 
on tests of verbal expression, digit span, spelling, serial position memory, 
mathematics, verbal comprehension, and story memory. Each of these measures 
assesses verbal working memory. 
B. Neuropsychiatric Disorders in dystrophinopathy 
Incidence of Attention-Deficit Hyperactivity Disorder (ADHD), Autism and 
Obsessive Compulsive Disorder is higher in DMD patients. 28, 29, 30, 31
Female carriers:                                                                                  
Majority of the female carriers are asymptomatic. About 2 - 20% of carriers 
have clinically evident muscle weakness. Weakness is usually progressive, mild 
to moderate, proximal and asymmetric with onset from 16 to 48 years. The arms 
are  more  affected  then  legs,  with  more  involvement  of  shoulder  abduction, 
elbow  flexion  and  knee  extension. Some  have  myalgia  or  cramps  without 
weakness. CPK levels are raised in 50 - 60% of carriers. Cardiac involvement is 
usually subclinical, although severe heart failure has been reported. In one cross 
sectional  study  dilated  cardiomyopathy  was  seen  in  8% and left  ventricular 
dilatation in 19% of carriers. Carriers do not have reduced life expectancy or 
increased risk of cardiac death. There is no association between the degree of 
muscle weakness and cardiomyopathy.  Around 20% of carriers have abnormal 
dystrophin  immunostaining  on  muscle  biopsy,  with  a  mosaic  pattern  of 
dystrophin positive and dystrophin negative fibers. 13, 20, 32, 33
Serum enzymes: 
1. Serum Creatine phosphokinase (CPK) concentration:
 Characteristic finding is raised serum CPK levels, at least 10 to 20 times (often 
50 to 200 times).  Levels greater than 10,000 mU/mL are common.  Serum CPK 
concentrations are high even in newborns, high CPK levels at birth can form 
basis of neonatal  screening for  DMD. Levels peak at  2 -  3 of age and then 
decline with increasing age at about 20% per year, due to progressive loss of 
dystrophic muscle fibers. Normal concentrations have been reported in  DMD 
associated DCM.  There is wide variability in serum CK concentration among 
DMD/BMD and carriers.4, 13, 20, 34  
2.  Serum Alanine transaminase and Aspartate transaminase           
Levels are raised in DMD and tend to correlate with CPK levels. 
3.  Other enzymes raised in DMD include Aldolase and Lactate 
dehydrogenase. Most of these are not specific for muscle and are generally not 
useful in the diagnosis of DMD. 13, 34
Electromyography (EMG): 
Needle EMG shows short duration, low amplitude polyphasic motor unit 
potentials. Fibrillation potentials, positive sharp waves and complex repetitive 
discharges may be detected due to denervation and some reinnervation in 
necrotic muscles. Over time, the motor units become very small and some areas 
become electrically silent. Electromyography is rarely required for diagnosis of 
DMD. 4, 13, 20
Molecular genetic testing: 
Molecular genetic testing is now the mainstay of diagnosis. 
1. Multiplex polymerase chain reaction (PCR)
Covers 19 exons at the two deletion hotspots, detects 90-98% of all deletions, 
although duplications and rarer mutations cannot be identified. 
2. Multiplex ligation dependent probe amplification (MLPA)
This test is more sensitive technique for detecting deletions. All 79 exons are 
covered by two sets of probes, with individual exons depicted as a single peak. 
This allows gene dosage abnormalities  to  be detected,  allowing detection of 
duplications  and  carriers  as  well  as  deletions.  If  MLPA testing  is  negative, 
DMD gene can be tested for point mutations. 
3. Direct sequence analysis of the DMD gene
Here DMD gene can be tested for point mutations. This is available on a 
research basis only due to labor intensive and costly nature.
4. Targeted high density oligonucleotide comparative genomic 
hybridization microarray
High resolution analysis of the gene can be done, allowing identification of 
deletions, duplications and unidentified deep intronic mutations. 13, 35
Muscle magnetic resonance imaging: 
MR is not usually performed for diagnosis, but may be useful to evaluate 
progression of muscle involvement over time. Abnormal signals are seen in 
gluteus maximus, adductor magnus, quadriceps, biceps femoris, rectus femoris 
and gastrocnemii muscles.
Muscle biopsy:                                                                                                     
It remains the gold standard for diagnosis.  
Light microscopy: 
Early stages
 Necrotic  or  degenerating  muscle  fibers  in  clusters  with  invasion/ 
phagocytosis by macrophages 
 Inflammatory  cells  at  perimysial  and  endomysial sites(predominantly 
macrophages and CD4+ lymphocytes)
 Clusters of regenerating muscle fibers with basophilic cytoplasm 
 Increased variability of muscle fiber size 
 Type 1 fiber predominance with some hyper contracted muscle fibers and 
type II B deficiency. 
 Internal nuclei and split fibers are not common as in other dystrophies.
Later stages
 Significant replacement of muscle fibers by fibro fatty tissue.13, 20, 36 
Detection of dystrophin in muscle biopsy sample:   
Dystrophin in muscle biopsy sample can be demonstrated by immunostaining or 
western blot  analysis,  using  antibodies  directed  against  different  epitopes  of 
dystrophin. Generally antibodies are directed towards amino terminus, carboxy 
terminus and rod domains.  Western blot  analysis  helps quantification of  the 
amount and size of protein. 13, 36 
Management
1. Physiotherapy:
It  aims  at  maintaining  muscle  function,  joints  mobility  and  preventing 
contractures.   It  should  begin  at  3  -  4  years  of  age  or  at  diagnosis,  with 
stretching of Achilles tendon, hip flexors and iliotibial bands as a daily regimen. 
Passive  stretching  and  night  time  ankle  foot  orthoses  (AFO)  are  used  in 
ambulant stage to delay development of contractures. Daytime AFO’s are not 
recommended as they may impede walking ability. Knee ankle foot orthoses 
may be used to prolong ambulation and standing. Their use may be of benefit as 
children who walk or stand beyond 13 years are less likely to require spinal 
surgery and contracture development is delayed. Manual wheelchairs should be 
provided early as they help in conservation of energy. Special seating and a 
head  rest  should  be  used  to  prevent  abnormal  postural  adaptations.  In  non- 
ambulant children passive or active assisted exercise should be continued for 
comfort and contracture prevention.  Breathing exercises are also an important 
component of physiotherapy. 13, 14, 20, 36
2. Corticosteroid Therapy
Prednisolone, prednisone and deflazacort are shown to be effective in DMD. 
Proposed mechanisms by which steroids improve strength in DMD:       
 Alteration of regulation of genes in muscle fibers                                     
 Slowing of the rate of skeletal muscle breakdown                             
 Reducing cytotoxic T cells/ anti-inflammatory effect 
 Lowering cytosolic calcium concentrations                                      
 Increasing myogenic repair. 37, 38                                                                     
Efficacy of treatment: 
Steroids improve muscle strength within 10 days,  maximal at  3 months and 
maintained up to 18 months, with improvements in functional testing (e.g. time 
to arise from supine to standing, time to walk nine meters) and muscle mass, as 
measured by urinary creatinine excretion. Non-randomized studies of long-term 
daily corticosteroids suggest that ambulation may be prolonged by up to three to 
five years, and that life expectancy is improved. Steroids also appear to have a 
positive effect on preservation of respiratory muscle strength, cardiac function 
and lowering the frequency of dilated cardiomyopathy, reducing the prevalence/ 
severity of scoliosis.39, 40, 41, 42, 43, 44 
Optimal age to begin and duration of treatment:                                      
There are no good studies on the optimal age to begin treatment or the optimal 
duration of  treatment. Common regimen is  to start  at  the time of decline of 
muscle strength and frequent falls and to stop when ambulation is lost. Some 
continue  steroids  beyond the  loss  of  ambulation,  for  the  possible  protective 
effect on respiratory and cardiac function.44, 45 Studies are lacking on the use of 
steroids in very young children and nonambulant patients. As muscle biopsies 
show inflammatory changes in the early disease, there is a case to use steroids 
in early disease and also in pre-symptomatic siblings, who have the disease. 
Inter compound efficacy: 
There  are  no  large  randomized  controlled  trials  comparing  deflazacort  with 
Prednisolone/  prednisone.  All  the  three  compounds  are  likely  to  be  equally 
effective, but have slightly different side-effect profiles.13                      
Regimes and  optimum dose:                                                                           
The  most  common daily  dosage  regimes  are  0.75  mg/kg/day  prednisone  or 
Prednisolone and 0.9 mg/kg/day deflazacort. Lower doses of 0.3 mg/kg/day still 
result in improvements in strength and function, but to a lesser degree, but may 
be used if side-effects require a decrease in dose. Higher doses of 1.5 mg/kg/day 
do not result in additional benefits, and alternate daily doses of 1.25 mg/kg and 
2.5 mg/kg did not achieve the sustained benefits of daily dosing. Other types of 
intermittent dosing such as Prednisolone 10 days on and 10/20 days off, and 
twice weekly schedule (5 mg/kg/dose) have also been showen to be beneficial. 
None of these regimes have been tested against the daily dosing schedules so 
that their relative efficacy in the long term is not known.44, 45, 46, 47, 48 
Monitoring for efficacy:                                                                           
Includes muscle strength, functional performance and FVC.                      
Side effects  :                                                                                              
Common side effects are weight gain (40%), hypertension, behavioral changes, 
growth retardation, cushingoid appearance (50%) and cataracts. Trials suggest a 
lower  incidence/  severity  of  weight  gain  with  deflazacort  compared  to 
prednisone, but higher incidence of cataracts. 
Vertebral  fractures  have  been  detected  in  32-40%  of  boys  on  long-term 
corticosteroids. Long bone fractures are also twice as likely compared to steroid 
naïve patients. Of the fractures occurring during the steroid therapy, 84.9% were 
in the lower limbs whereas the percentage of fractures between upper and lower 
limbs was evenly distributed during the no steroid period (52.5% and 47.2%). 
Increased  fracture  rate  in  steroid  treated  boys  could  be  due  to  prolonged 
independent ambulation and increased body weight. Other side effects include 
acne, excessive hair growth, and gastrointestinal symptoms. 
Monitoring has to be done for weight gain and bone density along with dietary 
advice and behavioral changes. If excessive weight gain occurs dose should be 
decreased.13, 40, 44, 49, 50 
Studies regarding the efficacy of prednisone in treating individuals with BMD 
are limited.
3. General management and surveillance
This includes symptomatic management and surveillance of orthopedic, cardiac 
and respiratory complications.
Cardiac disease
Cardiomyopathy without screening progresses asymptomatically until features 
of heart failure emerge, probably explained by the low physical activity due to 
weakness. Heart failure is primary cause of death in 10% of patients; this is 
expected to rise as life expectancy has increased for DMD patients.
Surveillance/ cardiac evaluation:
DMD/BMD patients - beginning at approximately 10 years, or at the onset of 
cardiac signs and symptoms, annual complete cardiac evaluation 
Female  carriers  -  initial  evaluation  to  be  done  in  late  adolescence  or  early 
adulthood, or earlier if symptomatic.
Evaluation includes an electrocardiogram and echocardiogram, with magnetic 
resonance imaging if required. Holter monitoring should be considered in 
patients with cardiac rhythm abnormalities. 
Management: 
There are indications of benefit with ACE inhibitors and beta blockers, alone or 
combined, in those with left ventricular dysfunction. Pre-treatment with ACE 
inhibitor  preserved systolic  function  with  mortality  benefit  (decreased 
mortality). Whether the addition of β blockade and/or prolonged glucocorticoids 
therapy will yield further benefit is unknown in presymptomatic group.  With 
ventilatory  support,  DMD  patients  survive  longer.  In  these  older patients 
arrhythmias play  a  prominent  role  in  survival  (cause  of  mortality).  Internal 
cardioverter  defibrillators  can  be  effective  in  them.  The  prophylactic  use  of 
antiarrhythmic agents has not been adequately studied. 23, 51
Respiratory disease 
Baseline pulmonary function tests and respiratory evaluations should begin at 
age 8 to 9 years and before ambulation is lost and then annually. 
Polysomnography for sleep disordered breathing and nocturnal hypoventilation 
should be performed at the time of loss of ambulation. 
Acute respiratory crisis due to infections require antibiotics, chest physiotherapy 
and respiratory support if needed. Nocturnal noninvasive intermittent positive 
pressure ventilation (NIPPV) is helpful for nocturnal hypercapnia. Benefits 
include increased quality of life, reduction and delay of onset of daytime 
hypercapnia and improved life expectancy to 25 - 30 years. Further progression 
of respiratory failure requires fulltime ventilation.13, 52, 53
Orthopedic issues
Maintenance of ambulation, postural support after loss of ambulation and also 
steroid therapy are important to prevent/ reduce contractures and scoliosis. 
Monitoring should begin before loss of ambulation. Surveillance 
X rays for scoliosis should be done yearly from 9 years of age. Once scoliosis is 
seen,  assessment for  surgical  correction has to be done.  The average age of 
scoliosis surgery is 14-15 years. To qualify for surgery, the scoliosis should be 
greater  than  25  degrees  with  vital  capacity  >  30%  of  predicted.  Scoliosis 
surgery  is  effective  in  correcting scoliosis,  preventing  further  deformity  and 
improved respiratory function, but has no effect on life expectancy. 13, 50, 54 
4. Bone health 
Maintenance of bone density is important to prevent fractures, particularly with 
steroid therapy.  Supplementation of 1000 mg/day of calcium and 400 units of 
vitamin D should be considered in all patients. Long bone fractures should be 
treated  with  early  mobilization  to  avoid  fracture  precipitating  loss  of 
ambulation.  Vertebral  fractures  can  be  treated  with  intravenous 
bisphosphonates. There is insufficient evidence for the use of prophylactic oral 
bisphosphonates.55 
5. Nutrition and gastrointestinal issues
Nutritional support should include advice on weight control, sodium restriction 
and calcium/  vitamin D intake.  In later  stages with difficulty  in  swallowing 
discussion of feeding tube is indicated. 
6. Other forms of therapies (under trial)
Amino glycosides  
Up to 15% of DMD patients have gene mutation known as a premature stop 
codon. Amino glycosides have been shown to over read stop codon mutations. 
In the mdx mouse, in vivo gentamicin therapy resulted in dystrophin expression 
at 10%-20% of that in normal muscle.  So it may have a role in patients with 
premature stop codons.4, 13, 56    
Oxandrolone
It  is  an  anabolic  steroid  with  anabolic  effect  on  skeletal  muscle  myosin 
synthesis.   It  is has effects similar to prednisone,  with fewer side effects.  A 
randomized,  prospective,  controlled  trial  showed significant  mean change in 
quantitative muscle  strength.  It  may be useful  before  initiating therapy with 
steroids as it  accelerates linear growth and may be beneficial in slowing the 
progression of weakness.  Long-term effects need to be studied.57 
Creatine monohydrate 
In a randomized, controlled, cross - over trial there was improved hand grip 
strength and increased fat free mass compared to placebo but no functional 
improvement was noted.58, 59 
Cyclosporine and Azathioprine
Cyclosporine was reported to improve clinical function in DMD. Due to reports 
of cyclosporine induced myopathy in patients receiving it for other reasons, its 
use in DMD remains controversial. Azathioprine has not been found to have 
any role.60
Histone deacetylase inhibitors 
Showen to produce improvement in mdx mouse by inducing the expression of 
the myostatin inhibitor follistatin. 
Genetic approaches
a. Gene therapy
Gene  therapy  aims  to  deliver  DNA  encoding  dystrophin  to  the  muscle. 
Problems with gene therapy include large size of gene,  immune response to 
protein and vector agents.  Approach of gene therapy has evolved form use of 
plasmids to viruses (adeno viruses) to deliver dystrophin sequences. Advances 
in viral delivery, including functional dystrophin mini- and micro genes and
gutted vectors with large insert capacity and lowered immunogenicity. These 
have showen good results in mdx mice.
b. Antisense oligonucleotide exon skipping: They can be used to redirect 
splicing and induce exon skipping to restore the reading frame, and are ideal for 
out of frame deletions or duplications. Dystrophin production in an mdx mouse 
model was seen after its use. Successful exon skipping was recently 
demonstrated after intramuscular injection of Antisense oligonucleotide into 
tibialis muscle in four patients. 
c.  PTC124:  It promotes  ribosomal  read  through  of  stop  codons,  allowing 
continuation of translation and production of a functioning protein. It restored 
dystrophin  levels  in  mdx mice,  with  an  associated  improvement  in  muscle 
function and decrease in CPK levels. Phase 1 studies in healthy adult volunteers 
showed that it is well tolerated. A Phase 2 study of 26 boys showed increased 
full length protein expression and decreased CK levels, but without significant 
functional changes or muscle strength.4, 13, 61, 62, 63
Myoblast transplantation and Stem cell therapy
Initially immortal myogenic cell line derived from adult satellite cells/ 
myoblasts were transplanted, this showed promise, but subsequent studies 
showed that they were rejected by the host cell mediated immune response.  In 
addition the cells that survived this immune destruction did not migrate more 
than few millimeters away from the injection site. 
Self-renewing,  immune-privileged stem cells  have been shown to proliferate 
longer than myoblast cells, to migrate from the circulatory system after intra-
arterial  injection  and  to  be  more  effective  than  myoblast  cells  in  muscle 
regeneration and dystrophin expression after implantation. 
Autologous myogenic stem cells with  ex vivo gene correction strategies were 
transplanted,  but  again limited by  the difficulty  in  producing an appropriate 
integrating vector to accommodate the large dystrophin/utrophin gene and the 
limited  life  span  of  the  myogenic  cells  obtained  from  Duchenne  muscular 
dystrophy patients.  
Bone marrow derived stem cells have shown to remodel muscle, may be useful 
to remodel dystrophic muscle. 
Recently, vessel associated fetal stem cells known as mesoangioblasts/ pericytes 
have been shown to provide widespread rescue of dystrophy after intra-arterial 
injection.4, 13, 63, 64
Utrophin
It is a protein homologue of dystrophin in the sarcolemma, may compensate for 
dystrophin deficiency if it is upregulated. Various factors that increase utrophin 
expression are being explored, such as heregulin and L-arginine, but most are 
still in the very early stages.65                        
Genetic counseling:
Genetic counseling is provided by trained healthcare professionals. 
 Assessment of risk to Family Members                                                        
a. Parents of a proband: Father of an affected male will not have the disease 
nor will he be a carrier of the mutation. Woman with an affected son will be an 
obligate heterozygote. Woman with more than one affected son and no other 
family history of DMD, have either germline mutation or mosaicism for a DMD 
gene mutation.   If  proband  is  the  only  affected  family  member,  he  may  be 
having a de novo DMD disease causing gene mutation or his mother may have a 
de novo DMD disease causing gene mutation or she has inherited a mutation 
from her mother (who is a carrier or has mosaicism). Molecular genetic testing 
combined with linkage analysis can determine the point of origin of a de novo 
mutation which is important for determining which members of the family are 
at risk. 
b. Siblings of a proband:  The risk to other siblings depends on the carrier 
status of the mother. If the mother has a disease causing mutation, the chance of 
transmitting it in each pregnancy is 50%. Male siblings who inherit the mutation 
will be affected and female siblings who inherit the mutation will be carriers. 
c. Offspring of a proband: Males with DMD usually die before reproductive 
age or  are too debilitated to reproduce.  Males with BMD and  DMD related 
DCM may reproduce.  All  the  daughters  are  carriers.  None of  the  sons  will 
inherit their father's DMD mutation. 
d. Other family members of the proband: Proband's maternal aunts and their 
offspring  may  be  at  risk  of  being  carriers  or  being  affected  (depending  on 
gender, family relationship and carrier status of the proband's mother).
Testing and Counselling of family member’s:                                            
All women related to an affected person by maternal linkage should be screened 
for  carrier  state.  Females  who are  identified  as  carriers  should  be  informed 
about risk for dilated cardiomyopathy and should be advised to be under regular 
monitoring. Before pregnancy they should be told about the risk of having an 
affected sibling and the availability of prenatal testing.
Materials and methods: 
Patients attending the neuromuscular clinic of our hospital were screened for 
inclusion into the study. 
Inclusion criteria:
Patients  with  Dystrophinopathy  (n=69;  68  boys  and 1  girl),  (  confirmed by 
absence or reduced levels of dystrophin on immunostaining of muscle biopsy), 
who  were  seen  in  the  Neuromuscular  clinic  of  Christian  Medical  College, 
Vellore during the period January  2007 - December 2008 were included in the 
study. 
Patients with the spectrum of Dystrophinopathies were broadly subdivided in 
group I (DMD) and group II (Outlier’s / BMD) as follows - 
1. Patients who lost ambulation before 12 years of age, irrespective of age of 
onset of disease were considered to have DMD, if they had not been treated. 
2. Patients who were ambulant even after 12 years, irrespective of age of onset 
of disease were considered to have either Outlier or Becker’s phenotype, if they 
had not been treated. 
3. On the other hand if patient was administered treatment before age of 12 
years, he was considered to be having DMD, if age of onset was within 5 years 
and Outlier or BMD if age of onset was > 5 years, to remove any confounding 
effect of treatment.
These patients were studied both prospectively and in a retrospective manner 
over 24 months during 2007 – 2008 when they were seen in the Neuromuscular 
clinic of our hospital.  
In the clinic,  patients  were seen by a multidisciplinary team consisting of  a 
Neurologist  (specialized  in  neuromuscular  diseases),  Physicians  form  the 
Medical  Genetics  and  Physical  &  Medical  Rehabilitation  department, 
physiotherapist  and  occupational  therapist  (specialized  in  neuromuscular 
diseases). Patients were assessed by the entire team and based on the inputs; 
plan of management was decided for each patient on an individualized basis. 
Role of Neurologist: Neurologist was involved in clinical assessment of muscle 
power and functional status, ascertainment of diagnosis, initiation of treatment, 
monitoring of treatment related improvement or side effects. 
Role of Physician from Physical and Medical department: The Physiatrist 
was involved in assessment of functional status, monitoring of motor power, 
goniometric changes and assessed the functional disability at periodic intervals 
and  give  valuable  advice  on  stretching  and  endurance  exercises  required, 
including respiratory exercises with incentive spirometer. The requirements, at 
different  stages  were  planned  in  discussion  with  the  Physiotherapists  and 
Occupational therapists and were individualized based on the requirement of the 
patient - including modification of household environment and providing wheel 
chairs. 
Role  of  Physician  from  Medical  Genetics  department:  The  Clinical 
Geneticist was involved in genetic testing of appropriate cases, counseling of 
family members regarding the disease and helping parents  of  the patient  on 
issues  of  planning  family  (future  pregnancies),  determing  of  risk  in  other 
siblings and screening of them with Serum Creatine phosphokinase to diagnose 
presymptomatic patients. 
Role of Physiotherapist and Occupational therapist: They were involved in 
assessment  of  muscle  power  and  functional  status,  physiotherapy  and 
occupational  therapy  with  special  reference  to  activities  of  daily  living, 
education about modification/ arrangements to be made at home for helping in 
performance of daily activities without much assistance. 
Each patient’s charts were analyzed for clinical data and data was also collected 
on  direct  examination  of  the  patient  during  follow  up.  All  patients  were 
scheduled  to  have  follow-up examinations at  six  month  intervals.  Life  time 
events were analyzed from birth with  respect to motor milestones, age of onset 
of  symptoms,  and first  symptom  noted,  age at  presentation  to  hospital  and 
diagnosis,  diagnostic  delay,  family  history,  nature  of  the illness  in  terms  of 
wasting,  weakness,  gait,  contractures,  functional  performance  on  specified 
tasks,  progression  of  the  illness  and various  milestones  achieved during  the 
course of illness like Gower’s sign, loss of ambulation, respiratory distress, toe 
walking, other gait abnormalities, spinal deformities, progression of falls, age at 
wheel chair or bed bound stage, cardiac status and age at death. Also noted was 
the progression of changes in the weight,  height,  CPK, complications if  any 
related to  steroid therapy.  Data  was collected  for  all  the  patients  as  per  the 
proforma attached. 
Muscle force was measured according to Medical Research Council scale of 2 
upper  and  2  lower  limb muscles.  We measured  muscle  power  in  following 
muscles:  right deltoid, right biceps, right quadriceps and right iliopsoas. We 
also calculated total/ cumulative MRC score by adding individual MRC scores 
of 4 muscles (Right deltoid, right biceps, right quadriceps and right iliopsoas). 
Functional grading was done for squatting and getting up, walking, getting up 
from chair and climbing stairs using GSCS system (Table 1). 66
Contractures were measured by goniometry. Goniometric measurements are in 
degrees around a set axis. To measure the angles around a joint, the goniometer 
is placed over the fulcrum of the joint. The stationary arm of the goniometer is 
placed  along  the  stationary  line  of  the  body,  and  the  movable  arm  on  the 
moving part of the body.  The patient is asked to move the joint in the desired 
direction, following the movement with the movable arm of the goniometer. 
The starting and ending value are recorded as noted on the goniometer. Thus the 
range of motion of the joint is calculated and noted if there is any lack of motion 
in the joint. 
Table 1. GSCS system for functional grading
Graded gait - A score assigned for 10 m of walking. 
  Grade 1 – normal.
  Grade 2 – mild waddling, lardosis and/or toe walking.
  Grade 3 - moderate waddling, lardosis and/or toe walking.
  Grade 4 – severe waddling, lardosis and/or toe walking.
  Grade 5 – walks only with assistance (i.e. canes, braces, crutches)
  Grade 6 – stands, unable to walk
  Grade 7 – confines to wheel chair
Graded stairs - A score assigned for walking up four stairs. 
   Grade 1 – climbs without assistance
   Grade 2 – supports one hand on thigh
   Grade 3 – supports both hands on thigh.
   Grade 4 – climbs in upright position but with aid of railing.
   Grade 5 – climbs while clinging to the railing with both hands
   Grade 6 – manages to climb only a few steps
   Grade 7 – unable to climb stairs.
Graded chair - A score assigned for rising from a chair to standing. 
   Grade 1 – normal
   Grade 2 – with wide base and/or difficulty, but without support
   Grade 3 – with support on one thigh
   Grade 4 – with support on both thighs.
   Grade 5 – with support on arms of chair or table
   Grade 6 – not possible.
Graded Gower – A score assigned for getting up from a sitting
   Grade 1 – normal
   Grade 2 – butt first manoeuvre, one hand on floor
   Grade 3 - butt first manoeuvre, two hands on floor.
   Grade 4 – unilateral hand support on thigh
   Grade 5 – bilateral hand support on thighs
   Grade 6 – arises only with aid of object (table, chair, etc)
   Grade 7 – unable to arise
Analysis of Data      
These patients were studied both prospectively and in a retrospective manner. 
For the purpose of analysis, patients were subdivided into four groups.
Group  I  a –  DMD  patients  who  were  seen  for  the  first  time  in  the 
neuromuscular clinic and diagnosed during the study period (2007 - 2008) 
Group I b – DMD patients who were on treatment before inclusion into the 
study and have follow up data for more than 2 years   
Group I c – DMD patients who were on treatment with follow up or treatment 
duration less than 2 years. 
Group II – BMD/ Outlier phenotypes
Stastical tests were used to determine significance of the values obtained and for 
comparison among groups. 
Analysis of Group I a patients for natural history of illness.
Group I a consisted of new patients whose course of illness was not modified by 
any therapeutic measures till presentation to our neuromuscular clinic. As they 
did not receive any treatment, they were considered as natural history group.  
Analysis of group I b patients for treatment outcomes.
Group I b was on treatment for more than 2 years before evaluation in current 
study. As group I b was under treatment, this group was compared with group I 
a (which had not received treatment) for various parameters. 
                    FLOW CHART SHOWING THE VARIOUS GROUPS 
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                   Group I c
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Results:
Patient population and study groups:
A total of 69 patients were studied. 68 were boys and 1 was girl. 60 (86.96%) 
patients were in group I, of them, 40 (57.97%) patients were in group I a, 16 
(23.18%)  patients  were  in  group  I  b,  and  4  (5.89%)  were  in  group  I  c.  9 
(13.04%) patients were in group II.     
Table 2.  Number of patients in each group during the study period
Frequency 
(%)
At first 
visit
At entry 
into study
At 6 
months
At 12 
months
At 18 
months
Group I a 40 40(100) 13(32.5) 6(15) 3(7.5)
Group I b 16 16(100) 13(81.25) 9(56.25) 7(43.75)
Group I c 4 4(100) 2(50) 2(50) 1(25)
Group II 9 9(100) 3(33.33) 2(22.22) 0
Total 69 69(100) 31(44.93) 19(25.54) 11(15.94)
Of those patients seen at entry into study, 11 (15.94%) patients had completed 
more than 18 months of follow up, 19 (25.54%) patients had completed more 
than12 months of follow up, 31 (44.93%) had completed more than 6 months of 
follow up (Table 2). 
Clinical features:
The mean age at onset of first symptom was 3.93 years in group I (among the 
subgroups, it was 3.6 years in group I a, 4.31 years in group I b, and 4.5 years in 
group I c ) and 8.44 years in group II. At presentation to our hospital, mean age 
was 7.7 years, 6.56 years, 7.5 years and 11.78 years respectively in groups I a, I 
b, I c and II.  At entry into the study, the mean age was 7.88 years in group I a, 
9.5 years in group I b, and 12.44 years in group II.  
Table 3. Age at onset of illness, presentation and entry into study
Mean age in
years  ( Standard 
Deviation,SD)
At first
Symptom At presentation
At entry into 
study
Group I 3.93(1.54) 7.38(1.98) 8.4(2.22)
Group I a 3.6(1.26) 7.7(2.15) 7.88(2.1)
Group I b 4.31(1.45) 6.56(1.46) 9.5(1.6)
Group I c 4.5(2.65) 7.5(1.3) 9(1.83)
Group II 8.44(1.51) 11.78(1.48) 12.44(1.51)
At entry into current study, patients in the group I b were older than those in 
group I a (mean age 9.5 v/s 7.88 years). There was delay between symptom 
onset and diagnosis in all groups (Table 3).  9 patients were told to have muscle 
disease elsewhere before they came to us. 
Developmental milestones: 
In group I, 35 (58.3 %) patients had delayed motor and of them 6 (10 %) had 
delayed language milestones also. In group II, 3/9(33.33%) had delayed motor 
milestones and 2/9(22.22%) had delayed language milestones. The mean age 
(SD) at walking without support was 1.75(.93) years in group I and 1.33(0.5) 
years in group II.  
Symptoms at presentation:
In group I, first symptom noted by parents was difficulty in getting up from 
squatting position without support in 32 (53.3%) patients, inability to run as fast 
as compared to their  peers in 10 (16.7%) patients, waddling gait in 5 (8.3%) 
patients, toe walking in 2 (3.3%) patients and repeated falls in 9 (15%) patients. 
One (1.6%) patient was diagnosed after he was found to have raised hepatic 
enzymes  while  being  evaluated  for  a  febrile  illness  elsewhere.  One  (1.6%) 
patient  had not  attained independent ambulation till  7 years of age when he 
presented to us. In group II, 8(88.9%) patients presented with difficulty to get 
up from squatting position and 1 (11.1%) patient presented with repeated falls.
Symptoms during the course of illness at various time intervals:
Table 4.  Age of onset of disease related symptoms
Group I Group II
Frequency 
(%)
Age in years 
(SD)
Frequency 
(%)
Age in years 
       (SD)
Uses Gower’s 59(98.3) 4.25(1.54) 9 (100) 8.33(1.73)
Waddling gait 44(73.3) 6.41(1.58) 9 (100) 9.78(1.64)
Repeated falls 51(85) 6.16(1.45) 9 (100) 9.89(1.45)
Toe walking 7(11.7) 4.71(1.60) 2 (22.22) 10(2.83)
Cannot run 59(98.3) 4.10(1.64) 9 (100) 8.56(1.74)
Calf 
enlargement 4(7.33) 6 1(11.11) 9
Dyspnoea  on 
exertion 1(1.7) 7 2 (22.22) 10.50(2.12)
Dyspnoea  at 
rest - - 1 (11.11) 13
The mean age at onset of difficulty to get up form squatting position without 
support was 4.25 years in group I and 8.33 years in group II. The mean age at 
onset of inability to run as fast as other peers was seen at 4.10 years in group I 
and 8.56 years in group II.  The mean age at onset of waddling gait was 6.41 
years  in  group I  and 9.78  years  in  group II.  The  mean age  at  onset  of  toe 
walking was 4.71 years in group I and 10 years in group II. Calf enlargement 
was seen in at mean age of 6 years in 4 patients of group I and at 9 years in one 
patient in group II. Among the symptoms during the course of illness, difficulty 
in getting up from squatting position and inability to run as other peers were 
common in all groups (Table 4).  
Table 5. Frequency/ age of appearance of mile stones among the subgroups.
Frequency (%) /
Age in yrs (SD)
Group I a 
(N = 40)
Group I b
(N = 16)
Group I c
(N = 4)
Group II
(N = 9)
Cannot walk without 
support
9 (22.5) 5 (31.26) 1 (25) 1 (11.11)
7.67(1.3) 9.60(1.67) 11 13
Cannot stand without 
support
9 (22.5) 3 (18.78) 1 (25) 1 (11.11)
8.33(1.58) 9.67(2.31) 11 14
Wheel chair bound 8 (20) 2 12.52) 1 (25) 1 (11.11)
8.63(1.30) 11.50(.71) 12 14
The mean age to reach wheel chair bound state was 8.63 years in group I a (8 
patients),  11.50 years  in  group I  b  (2  patients)  and 14 years  in  group II  (1 
patient) and 12 years in group I c (one patient). Overall there was trend towards 
prolonged ambulation in group I b compared to group I a (Table 5).
School performance and general intelligence
Poor school performance was reported by parents in 7 (11.7%) patients  and 
good in 22 (36.7%) patients of group I.  3 (5%) patients in group I had attention 
deficient hyperactivity disorder.    School performance was poor in 2 (22.22%) 
and good in 5 (55.56%) patients of group II. 
 Family history:                                                                                
Positive family history was seen in 14 (23.33%) patients of Duchenne muscular 
dystrophy.  6  patients  (8.7%)  had  affected  siblings,  2  patients  (2.9  %)  had 
affected cousins, and 6 patients (8.7%) had affected maternal uncle. One family 
had many members affected, including cousins and maternal uncles. One female 
patient who was symptomatic had no affected relatives.  
MRC scores on initial observation:
Table 6. MRC scores in individual muscles at first visit/ presentation
 Mean 
score (SD) Deltoid Biceps Iliopsoas Quadriceps
Cumulative 
score
Group I a 3.52(.75) 3.62(.65) 2.98(.89) 2.98(.95) 13.17(2.94)
Group I b 4.12(.42) 4.06(.30) 3.56(.47) 3.65(.47) 15.40(1.14)
Group I c 3.87(.62) 3.75(.5) 3.25(.5) 3.25(.5) 13.8(1.65)
Group II 3.72(.66) 3.77(.50) 3.27(.61) 3.16(.55) 14(2.12)
The mean MRC score in deltoid was 3.52, in biceps was 3.62, in iliopsoas was 
2.98,  in  quadriceps  was  2.98  and in  tibialis  anterior  was  3.72  in  group I  a 
patients.  In group I b patients the mean MRC scores were, 4.12, 4.06, 3.56, 
3.65, and 3.84 respectively in deltoid, biceps, iliopsoas, quadriceps and tibialis 
anterior muscles. In group II patients MRC scores were, 3.72, 3.77, 3.27, 3.16 
and 3.94 respectively (Table 6). 
Table 7.  MRC scores at entry into study in all patients
  Mean 
score
      (SD) 
Deltoid Biceps Iliopsoas Quadriceps Cumulative score
Group I a 3.46(.75) 3.57(.69) 2.93(.92) 2.87(1.02) 12.93(3.06)
Group I b 3.62(.42) 3.65(.5) 2.9(.68) 3.03(.8) 13.2(2.19)
Group I c 3.5(.40) 3.75(.5) 3(.81) 3.25(.5) 13(1.77)
Group II 3.83(.79) 3.66(.43) 3.05(.46) 3.11(.54) 13.33(1.52)
The cumulative MRC score (Sum of MRC scores of deltoid, biceps, iliopsoas 
and tibialis anterior) at first visit was 13.17 in group I a, 15.40 in group I b, 14 
in group II and 13.8 in group I c (Table 6). The cumulative score at entry into 
the study was 12.93 in group I a, 13.2 in group I b, 13.3 in group II and 13 in 
group I c (Table 7). Across all groups, weakness was prominent in the pelvi-
femoral muscles and both iliopsoas and quadriceps were equally involved in 
26/69 (37.68%) from the onset of illness. Power in quadriceps was less then 
iliopsoas in 13(18.84%) patients. 
Table 8. Facial weakness and axial weakness
Frequency
      (%) Group I a Group I b Group I c
Group II
Facial weakness
Mild 14 (35) 7 (43.75) 3 (75) 2 (22.22)
Moderate 12 (30) 4 (25) 1 (25) 1 (11.11)
Neck flexor weakness
Mild 29 (72.5) 10 (62.5) 4 (100) 8 (88.89)
Moderate 8 (20) 5 (31.25) 1 (11.11)
Severe 2 (5) 1 (6.25)
Axial weakness (Truncal)
Mild 13 (32.5) 2 (12.5) 5 (55.56)
Moderate    16 (40) 12 (75) 3 (75) 3 (33.33)
Severe 11 (27.5) 2 (12.5) 1 (25) 1 (11.11)
Facial  weakness  was  present  in  44  (63.78%)  patients,  mild  in  26  (37.68%) 
patients and moderate in 18 (26.08%) patients.  Neck flexors weakness was seen 
in  all  patients,  mild  in  51(73.91%),  moderate  in  15(21.74%)  and  severe  in 
3(4.3%) patients.  Axial  (Truncal)  muscle  weakness was seen in  all  patients, 
mild  in  20(28.99%),  moderate  in  34(49.27%)  and  severe  in  15(21.74%) 
patients). Axial weakness was profound in group I patients, (moderate to severe 
in 67.5% patients of group I a, 87.5 % of group I b and in all patients of group I 
c) (Table 8).
Functional grades:
Table 9.  Functional (GSCS) grades at entry into study 
Mean 
(SD) Squatting Walk Chair Stairs
cumulative 
score
Group I a 4.58 (1.93) 3.55(1.99) 3.40(1.66) 4.18(1.89) 15.72(7.15)
Group I b 4.03(1.52) 3.31(1.62) 3.13(1.26) 4.13(1.54) 14.69(5.63)
Group I c 4(1.41) 3 (.82) 2.75(.96) 4 13.75(3.09)
Group II 4.67(1.33) 3.22(1.72) 3.22(1.30) 3.78(1.48) 14.89(5.64)
The mean score in group I a for getting up from squatting position was 4.58, for 
walking it was 3.55, for getting up form chair it was 3.40 and for climbing stairs 
it  was  4.18.  For  those  in  group  I  b  scores  were  4.03,  3.31,  3.13  and  4.13 
respectively. The cumulative scores were 15.72 in group I a, 14.69 in group I b, 
14.89 in group II and 13.75 in group I c (Table 9). 
Distribution of GSCS and MRC score in patients of a given age. 
The mean values of GSCS scores and MRC scores of patients presenting at a 
particular age was taken and plotted against the age of the patients of group I a 
and group I b.  Over time there was gradual decline in MRC scores and GSCS 
scores during the course of illness. These occurred at a slower rate in group I b 
(Figures 3, 4, 5 and 6).
Over all MRC and GSCS scores were better in treated group (group I b) across 
all age groups compared to the natural history group (group I a).  Patients in 
group I b were younger than the other groups at presentation to the hospital and 
were older than the other groups when they were first  seen during the study 
period.  
Comparison  of  grade  of  walking  and power  in  iliopsoas/  quadriceps  in 
group I a patients. 
With disease progression, there was decline in the muscle power and worsening 
of the functional status, evident by increasing GSCS score. As the power in the 
lower limb muscles decreased there was worsening of gait, even with power 
less  than  3,  patients  with ambulant  with moderate  to  severe  waddling;  only 
when power was less than 2, they lost ambulation.  So functional ability and 
decline in MRC score progress over time, but functional ability appears to be 
relatively  preserved  even  with  severe  muscle  weakness  (Figure  7).  This 
correlation was statistically significant with 2 sided Pearson chi square value, p 
<  0.01.  In  addition  loss  of  ambulation  correlated  more  with  power  in 
quadriceps,  as  power  became  less  than  2,  most  patients  lost  independent 
ambulation.  
Deep  tendon  reflexes  were  absent  in  13(18.84%)  patients,  only  ankle  jerk 
elicitable in 41(59.42%) patients, reflexes were sluggish in 5 (7.24%) patients, 
and normal in 10 (14.28) patients.  Patients with absent deep tendon reflexes 
were those with advanced disease.  
Spinal deformity was present in 66 (95.65%) patients, increased lumbar lardosis 
in 53(76.68%), scoliosis in 6(8.79%) and both in 7(10.14) patients.  23(33.33%) 
patients had wide based stance. 
Contractures  were  commonly  seen  at  ankle  in  56(81.16%),  at  knee  joint  in 
12(17.39%) patients, at hip joints in 8(11.39%) and at elbow joint in 1(1.4%) 
patient.  There was progressive increase in the degree of contractures over the 
course of illness (Table 10). The degree of ankle contracture in the group 1b, 
was steadily increasing at the various timelines, when compared to group 1a, 
and these patients (1b) with better MRC scores, continued to be ambulant. The 
natural history group (1a) had lower MRC scores across time lines and 9/40 had 
lost ambulation under the age of 10. 
Table 10. Ankle contracture (in degrees)
Mean (SD)
At start of 
study 6 months 12 months 18 months
Group I a 12.50(5.88) 11.54(3.75) 13.33(5.16) 13.33(7.63)
Group I b 13.13(7.04) 14.17(6.68) 16.67(7.07) 18.57(6.9)
Group I c 15(5.77) 20 20 20
Group II 14.44(5.27) 16.67(5.77) 20
Serum Creatine phosphokinase levels:
Mean Serum CPK at presentation was 11354.58(7327.2) in group I a patients, 
12032 (5783.09) in group I b patients, 10634 (3880.42) in group II patients and 
13487(5119.29)  in  group  I  c  patients.  When  the  mean  Serum  CPK  values 
analyzed according to age, values were more than 50 times normal during first 
decade (range – 1395 to 33000) after which there was decline in the values as 
the disease progressed (range – 1512 to 7456) (Figure 8).  We had 3 bed bound 
patients, first patient was 8 years old boy with Serum CPK value of 1395, and 
second boy was 12 years old with under follow up since 18 months with Serum 
CPK values of 1512, 2321 and 3863. Third boy was of 15 years, bed bound 
since 12 years of age with Serum CPK of 763.
Analysis of serial Sr CPK values in 5 of our patients with follow up more than 3 
years also showed that there was gradual decline in the levels with increasing 
age and disease duration in most of them (Figure 9).
Electromyogram (EMG):
EMG was available for analysis in 49 (71.01%) patients, On Nerve conduction 
studies, CMAP’s were of normal amplitude in 25(51.02%) patients, reduced in 
amplitude in both upper and lower limbs in 11(22.45%) patients,  reduced in 
lower  limbs  in  9(18.37%) patients  and reduced  in  upper  limbs  in  4(8.16%) 
patients.   Needle  EMG showed spontaneous activity  in  the form of positive 
sharp waves in 4 (8.16%) patients and positive sharp waves with fibrillations in 
one (2.04%) patient. Interference pattern was myopathic in all the 49 patients.  
Electrocardiogram (ECG) changes:
ECG’s of was analyzed in 35 patients (30 of Duchenne’s phenotype and 5 of 
Becker’s phenotype).  In 30 patients with Duchenne’s phenotypes (groups I), 
ECG showed sinus tachycardia in 15 (50%) of the patients, prominent R in V1 
(> 4 mm) in 29 (96.66%) patients, R > S in V1 in 19 (63.33%) patients, R > S in 
V2  in  21  (70%)  patients.  All  these  features  were  more  common  in  the 
nonambulant  group  than  the  ambulant  group  in  these  patients.  In  Becker’s 
phenotypes  (group  II,  5  patients),  one  (20%)  showed  sinus  tachycardia,  all 
5(100%) had R wave in V1 > 4mm, 3(60%) patients had R > S in V1 and 
4(80%) patients had R > S in V2 (Table 11).
Table 11. Electrocardiogram changes in 35 patients
        Group    
    (Frequency)
   heart rate  
   > 100
  R in V1
 > 4mm
  R/S in V1  
       > 1
 R/S in V2 
      > 1
Duchenne’s phenotypes (group I)
Nonambulant (7) 5(71.42%) 7(100%) 5(71.42%) 6(85.71%)
Ambulant (23 ) 10(43.47%) 22(95.65%) 14(60.87%) 15(65.2%)
Total 15(50%) 29(96.66%) 19(63.33%) 21(70%)
Becker phenotypes/ Outlier’s (group II)
Nonambulant (1) 1 1
Ambulant (4) 1(25%) 4(100%) 3(75%) 3(75%)
Total 1(20%) 5(100%) 3(60%) 4(80%)
Echocardiography (Echo) findings:
Echocardiography reports of 30 patients were analyzed.
Table 12. Echo findings (mean values and standard deviation)
        Group Ejection 
fraction (%)
LVESV LVEDV LVEDD
Duchenne’s phenotypes (group I)
Nonambulant (11) 61.91(3.36) 18.73(6.8) 44.73(12.61) 34.36(3.04)
Ambulant (15 ) 60.00(2.33) 21.67(14.19) 44.27(10.14) 32.07(3.95)
Becker phenotypes/ Outlier’s (group II)
Nonambulant (1) 57 36 82 44
Ambulant (5 ) 61(2.64) 24.00(6) 60.33(19.03) 38.33(3.21)
The mean Ejection Fraction (EF) was more than 60% in group I a, I b and I c 
patients. One patient in group II had EF of 57%, who had lost ambulation. Left 
ventricular end systolic volume (LVESV) and end diastolic volume (LVEDV), 
Left  ventricular  end  diastolic  diameter  (LVEDD)  were  normal  in  group  I 
patients.  They  were  increased  in  one  patient  of  group  II.  Wall  motion 
abnormalities  were  not  documented  in  any  of  these  patients.  There  was  no 
difference  in  the  values  between  ambulant  and  non  ambulant  groups  in 
Duchenne’s  phenotypes.  Echo  parameters  were  different  in  the  Becker’s 
phenotype patients who were ambulant and nonambulant  (increased LVEDV 
and LVEDD) (Table 12).
Histopathological findings on muscle biopsy: 
All  showed  myopathic  features.  Overall  architecture  was  preserved  in  31 
patients  (44.9%),  mildly disrupted in 25 (36.2%) and effaced in 13 (18.8%) 
patients.  Commonly  seen  changes  were  fiber  size  variation,  atrophic  and 
hypertrophic  fibers,  ring  fibers,  regenerating  fibers,  myophagocytosis,  and 
necrotic fibers. In addition fibrosis was seen in endomysial region in 27(39.1%) 
patients, perimysial regions in 4 (5.7%) patients or in both places in 38(55.1%) 
patients. It was focal in 2(2.9%) patients, mild in 35(50.7%) patients, moderate 
in 14(20.3%) patients and extensive in 18(26%) patients. Fatty infiltrates was 
seen  in  interfasciular  in  5(7.2%)  patients,  in  intrafascicular  region 1(1.45%) 
patient or in both regions in 38(55.1%) patients. Inflammatory infiltrates were 
seen in 21 patients, in perivascular region in 16(23.2%) patients and endomysial 
region in 5(7.16%) patients.  The time of disease onset to biopsy was less in 
patients showing inflammatory infiltrates. Type 1 fiber predominance was seen 
in  8(11.6%)  patients  and  type  2  fiber  predominance  was  seen  in  2(2.9%) 
patients. 
Immunostaining for dystrophin:
 44(63.78%) patients had absence of dystrophin  2 and  3. 16(17.78%) patients 
had absence of 1,  2 and 3. 1(1.4%) patient had absence of dystrophin 1 and 2. 
4(5.8%) patients had absence of dystrophin 2. 4(5.8%) patients had absence of 
dystrophin 3. Revertant fibers were seen in 14(20.28%) patients, few in 4(5.8%) 
and occasional in 10(14.5%) patients.
Treatment aspects:
Patients were initiated on physiotherapy / and medications.  In the present study 
group all were on regular physiotherapy and stretching exercises. They were 
also initiated on breathing exercises with incentive spirometer. 
Table 13.  Medications, dosage and duration.
Parameter Group I a Group I b Group I c Group II Total (%)
Prednisolone 1 4 1 2 8(11.59)
Deflazacort 26 12 3 5 46(66.66)
No treatment 13 2 15(21.74)
Mean age of 
starting 
treatment
 in years (SD)
7.23
(1.90)
6.69
(1.74)
7.25
(.96)
10.57
(1.27)
Follow up in 
months (SD) 
5.6
(6.16)
43.13
(25.1)
15.5
(3)
9.89
(15.50)
8 (11.59%) patients were on medications with Prednisolone (mean dose - 1 mg 
per kg body weight) and 46 (66.66%) patients were on deflazacort (mean dose 
of 0.96 per kg body weight), given on alternate days. 15(21.74%) patients were 
not  initiated  on  medication  as  they  were  in  advanced  stage  at  the  time  of 
presentation. The mean duration of follow up was 5.60 months, 43.13 months, 
9.89  months  and  15.50  months  in  groups  I  a,  I  b,  II  and  I  c  respectively. 
6(8.69%) patients had follow up of more than 6 years, 12(17.39%) patients had 
24 - 48 months follow up, 8(11.59%) patients had 13 -23 months follow up, 
16(23.19%) had 7 -12 months and 27(39.13%) patients had less than 6 months 
follow up (Table 13). In addition to steroids all patients were on Calcium and 
Potassium supplementation.
Treatment related complications
On evaluation during the study period, patients treated with steroids in group I b 
(16  patients)  had  weight  gain.   On  comparison  with  healthy  controls,  at 
presentation to hospital before starting steroids, one (6.25%) patient had BMI 
above  95  th  percentile  for  age,  3(18.75%)  patients  were  more  than  85  th 
percentile,  3(18.75%)   had  BMI  above  the  50  th  percentile  for  age,  and 
9(56.25%) had BMI below the 50 th percentile for the age. When seen during 
the  study  period  (when  they  were  on  steroids  for  more  than  2  years),  one 
(6.25%) patient had BMI more than 95 th percentile for age, 3(18.75%) had 
above 85 th percentile for age, 6(37.5%) had BMI above the 50 th percentile for 
age and 6(37.5%) were below the 50 th percentile for the corresponding age 
(Figure  10).  There  was  no  significant  difference  in  Prednisolone  group and 
deflazacort group in terms of weight gain in our study.
On comparison of height of group I b patients with the normative for the same 
age (ICMR values),  at  presentation to the hospital  (before  starting steroids), 
8(50%)  patients  were  above  the  50  th  percentile  of  height  for  the  age  and 
8(50%)  patients  were  below the  50  th  percentile.  None  of  the  patients  had 
values below the 10 th percentile (Figure 11).
On assessment during the study (when they were on steroids for than 2 years), 
16(100%) patients were below the 50 th percentile and out  of these 8(50%) 
were  below the  10  th  percentile  for  the  corresponding  age  matched  values 
(Figure 12).   This was probably related to the steroid therapy.  Two (12.5%) 
patients had osteoporosis documented on DEXA scan and one (6.25%) patient 
had fracture  of  femur  shaft  during physiotherapy (stretching exercises).  One 
patient was found to have features of depression and was initiated on Sertaline 
in consultation with Psychiatrist.
Outcome measures:
For outcome measures, patients of group I b were compared with group I a. 
Comparison  was  done  to  analyze  the  differences  in  them  with  respect  to 
changes in functional grade (GSCS) and MRC scores over time, and age at loss 
of ambulation. 
The  mean  functional  grade  (GSCS)  for  all  parameters  at  a  given  age  was 
calculated  by  taking mean values  of  all  patients  presenting  at  that  age.  For 
example GSCS for squatting at 7 years was derived from the mean grade of 
squatting of all patients who had entered the study at 7 years of age.
 From analysis of this data it was evident that there was gradual decline in the 
functional status (seen as increase in the GSCS score) over the course of illness 
up to 7 or 8 years after which there was steep decline in the scores in group I 
patients. In the group I b patients there was decline in the grades but at slower 
rate than group I a (Figure 13). 
The mean MRC score and cumulative score was derived in the same way as the 
GSCS grade was done. On analysis the data there was gradual decline in the 
muscle  power over the first  8 years  and then rapid progression (Figure 14). 
There was  gradual  progression  of  GSCS and MRC grades  over  time  in  the 
treatment group. On comparison with the group I a curves, it was seen that that 
decline was slower and each disease related milestones appeared at a later age 
in group Ib.   
Mean GSCS was lower (14.69 v/s  15.72) and mean MRC score was higher 
(13.2 v/s 12.93) in group I b, and the age at entry into the study was higher in 
group I b (9.56 v/s 7.88) (Table 14). Overall there was shift in the curve to the 
right side, that is all disease related milestones occurred at a comparatively later 
age in treated groups.    
Table 14. Statistical analysis: 
Mean 
(Std deviation)
   Mean  age  at 
entry into study 
Mean  GSCS  at 
entry into study 
Mean  MRC  at 
entry into study
Group I a 7.88(2.1) 15.72(7.15) 12.93(3.06)
Group I b 9.56(2.2) 14.69(5.63) 13.2(2.19)
Mann  Whitney 
test (sig -2 tailed) 0.011 0.935 0.898
The difference in the MRC scores and GSCS scores was not significant between 
the two groups but there was significant difference in the mean age between the 
two groups.  That  is group I b patients have preserved power and functional 
ability for/ at a given age than natural history group (group I a) (table 14). 
7(17.5%) patients in group I a were confined to wheel chair before 10 years of 
age; in group I b all patients below 10 years were ambulant till follow up, two 
(12.5%) patients were ambulant with support (Table 15).  
Table 15. Comparison of ambulation in group I a and I b.
Parameter/age in years 6 7 8 9 10 11 12
Group I a (40 patients)
Cannot  walk  without 
support 2 2 3 1 1
Cannot  stand  without 
support 2 2 4 1
Wheel chair bound 2 1 4 1
Group I b (16 patients)
Cannot  walk  without 
support 1 1 1 2
Cannot  stand  without 
support 1 2
Wheel chair bound 1 1
Two (12.5%) patients in group I b lost  independent ambulation and became 
wheel  chair  bound after  11 and 12 years  of  age  respectively.   In  our  study 
group,  loss  of  ambulation before  10 years  in patients  on treatment  was less 
common, but patients not on treatment usually lost ambulation before 10 years 
of  age.  Group I  a patients  lost  ability  to  walk without  support  at  ealier  age 
(mean age -7.67 years) compared to group I b (mean age – 9.60 years), which 
was significant (p = 0.034). Group I a worsened further to reach wheel chair 
stage again at an earlier age (mean age – 8.62 years v/s 11.50 years), which was 
significant statistically (p = 0.019) (Table 16).
 Table 16. Statistical analysis – t test for equality of means
Parameter Frequency Mean(SD) Sig. (2-tailed)
Cannot walk without 
support
  Group I a 9 7.67(1.32) .034
  Group I b 5 9.60(1.67)
Wheel chair/bed bound   Group I a 8 8.62(1.30) .019
  Group I b 2 11.50(.71)
Analysis of a subgroup of 7 patients in group I b
In group I  b,  7(43.75%) patients  were seen in  the clinic  more than 3 times 
during the study period.  Their age at presentation was 6.43 years (1.99), age at 
entry into study was 9 years (2.58), age at onset of first symptom was 4 years 
(1.63), age at onset of difficulty to squat and get up was 4 years (1.63), inability 
to run was 4.57 years (1.9), inability to walk without support was at 8 years 
(1.41) in 2(28.57%) patients.   Facial weakness was seen in 5(71.42%) patients 
at  entry  into study,  mild  in  3(42.86%) and moderate  in  2(28.57%) patients, 
during  the  study  period  one  patients  developed  mild  facial  weakness  and 
another patient with mild weakness, worsened to moderate weakness.  Axial 
was mild in 1(14.29%) patient, moderate in 5(71.42%) patients and severe in 
1(14.29%)  patient.  Over  the  study  period  there  was  gradual  progression  of 
GSCS grade, about 3 units per year. There was decline in the MRC scores, in 
the range of 0.18 to 1 units per year. At entry into the study 6(85.71%) patients 
had  GSCS score  of  9-15,  and  one  (14.29%)  patient  had  score  in  the  range 
16-21(Table 17).
Table 17.  Parameters during study period in 7 patients of group I b
 At first At entry At 6 At 12 At 18 
visit months months months
Mean GSCS 13.29
(3.09)
14.71
(3.86)
16.29
(4.86)
17.86
(5.58)
Mean MRC
score 15.14(.9)
13.79
(1.65)
13.29
(1.87)
13.07
(2.05)
12.79
(2.1)
Change  in 
GSCS 2.86(3.24) 3(2.58) 3.04(2.4)
Change  in 
MRC .93(.61) 1(1.53) .57(.84) .18(1.12)
GSCS grade change 
> 21 1
16-21 1 4 4 3
9-15 6 3 3 3
<9
Sr CPK 9690.86
(4691.46)
8318.20
(4753.15)
13581.67
(3732)
11928
(7148.72)
16951
(11385.8)
Over the follow up period, 3 (42.86%) patients worsened with GSCS in 16-21 
range and at 18 months one (14.29%) patient worsened further to enter GSCS > 
21 range.  There was weight gain with BMI at first visit being 15.3, 16 at entry 
into study and 16.74 at end of the study period.  There was decrease in the 
number of falls over the study period. 
Table 18.  Frequency of falls during the study period.
Frequency At start of study
At  6 
months
At  12 
months
At  18 
months 
Rarely falls ( < 1 per wk) 1(14.3%) - 3(42.9%) 4(57.1%)
Occasional falls 
(2 – 4 / wk) 3(42.9%) 5(71.4%) 3(42.9%) 3(42.9%)
Daily falls 2(28.6%) 2(28.6%) 1(14.3%) -
Repeated falls 
( > 4 per day) 1(14.3%) - - -
1(14.29%) patient used to have repeated falls, 2(28.58%) patients used to have 
daily falls, 4(57.16%) patients used to have occasional or rare falls when they 
had evaluated at entry into study. At the end of study all 7(100%) patients were 
having occasional or rare falls with none of them having repeated falls (Table 
18). Ankle contractures were seen to increase over time, at  entry into study, 
2(28.58%) patients had 10 degrees and 4(57.16%) patients had 20 degrees of 
contractures. At the end of study, 2(28.58%) patients had 10 degrees, 4(57.16%) 
patients had 20 degrees and 1(14.29%) patients had 30 degrees of contracture. 
Comparison of GSCS grades with other parameters in group I
Patients with GSCS > 21, compared to patients with GSCS < 15 had greater 
delay in onset to diagnosis (4.9 v/s 3 years), greater degree of ankle 
contracture (18 v/s10.42), lower Sr CPK (4590.83 v/s 13283), severe grades 
of facial and axial weakness and more frequency of scoliosis in addition
to lumbar lardosis. 
Table 19. GSCS at presentation and associated clinical variables
GSCS/
parameters
< 15
(N=39)
16 – 21
(N = 9)
> 21
(N =12)
Onset (yrs) 3.77 (1.42) 4.22 (1.92) 4.25(1.66)
Presentation (yrs) 6.64(1.41) 9(1.32) 8.58(2.71)
onset – presentation 2.85(1.34) yrs 4.78(1.85) yrs 4.08(2.61) yrs
Ankle contractures 11.03 (5.98) 13.33 (5) 18.33 (3.89)
Sr CPK 12588.33 11464.89 8876.92
MRC score 15.10 (1.43) 13(1.64) 10.25 (3.01)
Facial weakness
Mild 
Moderate
18(46.2%)
4(10.3%)
5(55.6%)
2(22.2%)
1(8.3%)
11(91.7%)
Axial weakness
Mild
Moderate
Severe
2(5.1%)
35(89.7%)
2(5.1%)
1(11.1%)
7(77.8%)
1(11.1%)
1(8.3%)
3(25%)
8(66.7%)
Spinal deformity
Scoliosis
Lardosis
Both
2(5.1%)
35(89.7%)
2(5.1%)
2(22.2%)
6(66.67%)
1(11.1%)
5(31.7%)
4(33.3%)
3(25%)
On Statistical analysis there was significant correlation between axial/ facial 
weakness and grades of GSCS (p < 0.01). With other parameter there was 
no significant correlation (Table19).   In patients with GSCS > 21, on 
histopathology, architecture was effaced in 50 % compared to 10.3% in 
GSCS < 15 group.  There was no stastical correlation between other 
variables and grades of GSCS (p > 0.05) (Table 20).
Table 20. GSCS at presentation and associated Histopathological variables
GSCS/
parameters
<  15
(N=39)
16 – 21
(N = 9)
> 21
(N =12)
Architecture
           Normal 21(53.8%) 2(22.22%) 3(25%)
           Mild 
loss 14(35.9%) 5(55.6%) 3(25%)
           Effaced 4(10.3%) 2(22.22%) 6(50%)
Inflammation
Focal 6(15.4%) 1(11.1%) 1 (8.3%)
Mild 5(12.8%) 1(8.3%)
Moderate 1(2.6%) 1(11.1%)
Severe
Fibrosis grade
Mild 18(46.2%) 5(55.6%) 6(50%)
Moderate 9(23.1%) 1(11.1%) 3(25%)
extensive 11(28.2%) 3(33.3%) 2(16.7%)
Dystrophin 
absent 
2,3
22(56.4%) 7(77.8%) 7(58.3%)
1,2,3 13(33.3%) 2(22.2%) 1(8.3%)
2 1(2.6%) 1(8.3%)
3 1(2.6%)
1,2 1(2.6%)
Revertant 
fibers
Few
2(5.1%) 1(11.1%) 1(8.3%)
occasional 7(17.9%) 1(8.3%)
Ankle contractures and disease pattern in group I a and I b. 
31 patients had 10 degrees and 19 patients had 20 degrees of ankle contracture. 
5 did not have contracture at entry into the study (Table 21).
Table 21. Ankle contracture and disease pattern
Groups
 
Contracture in 
degrees
            Ambulant Total
No Yes  
Group I a
 
 
absent 0 3 3
10 2 22 24
20 7 5 12
total 9 30 39
Group I b
 
 
absent 0 2 2
10 0 7 7
20 5 2 7
total 5 11 16
There  was  increase  in  the  degree  of  contracture  at  the  ankle  joints  with 
increasing age of the patient.  With worsening of the MRC score and GSCS 
grades, there was progression in ankle contractures. Most of the patients with 
greater degree of contracture were of older age, having low MRC score, higher 
GSCS score.  Most of the patients who were ambulant, both in group I a and I b 
were having 10 degrees of contracture and most of the nonambulant patients 
were having greater degrees of contractures.  During the course of illness there 
was a period during which these patients were ambulant and had milder grade 
of contracture, probably as a compensatory measure for better locomotion,14 but 
over time as the weakness in the muscles increased there was worsening of the 
contractures and the loss of balance between compensatory measures is lost, 
progressing to loss of ambulation (Table 22).  
                                             Discussion:
Dystrophinopathies were commonest among the various muscle diseases seen in 
our neuromuscular clinic. They constituted 45.01% (131 of the 291 diagnosed 
cases of primary muscle diseases) of all the primary muscle diseases seen in the 
clinic over the last 5 years.
The present study was carried out on 69 patients (68- boys; 1- girl). The mean 
age of the patients at  entry into the study was 7.88(2.1)  years in group I a, 
9.5(1.6) years in group I b, 9(1.83) years in group I c and 12.44(1.51) years in 
group II.   Group I b patients were relatively older than those in group I a at 
entry into the study. 
In our study, 55.1% of patients had delayed motor milestones. The mean age at 
walking without support was 1.75(.93) years in group I and 1.33(0.5) years in 
group II.   These  were comparable  to  the  average  of  18 months  reported  in 
literature. One boy aged 7 years in our series never walked without support.  In 
addition  11.6% had  delayed  language  milestones.   Both  delayed  motor  and 
language milestones have been reported in other studies.5, 67, 68
The mean age (SD) at first symptom onset was 3.93(1.54) years in group I.  In 
other studies of Duchenne Muscular dystrophy, the mean age at onset were 4.8 
years  (Gulati  et  al,  2005),  5.4 years  (Ahuja et  al,  2000),  3 years,  8  months 
(Thong et al, 2005) and 2.4 years (Anthonie et al, Dutch survey) 69, 70, 71, 72 Age of 
first symptom onset in our study was similar to that in study by Thong et al and 
Gulati et al. Onset was at earlier age in Dutch study compared to other studies. 
The mean age at first symptom in group II was 8.44 (1.51) years. 
In group I, first symptom noted by parents was difficulty in getting up from 
squatting position without support in 32 (53.3%) patients, inability to run as fast 
as compared to their  peers in 10 (16.7%) patients, waddling gait in 5 (8.3%) 
patients, toe walking in 2 (3.3%) patients and repeated falls in 9 (15%) patients. 
One (1.7%) patient was diagnosed after he was found to have raised hepatic 
enzymes  while  being  evaluated  for  a  febrile  illness  elsewhere.  One  (1.7%) 
patient  had not  attained independent ambulation till  7 years of age when he 
presented to us. In a similar study of Duchenne’s Muscular dystrophy (Thong et 
al, 2005), the most common presentation was developmental delay, followed by 
frequent falls, lower limb weakness, calf enlargement, unusual gait and frequent 
cramps.71  In another study (Anthonie et al, Dutch survey) 47.6% patients had 
locomotor  problems  initially  and  3  cases  were  diagnosed  co-incidentally  in 
presymptomatic stage by elevated creatine kinase.72 
In group II, 8(88.9%) patients presented with difficulty to get up from squatting 
position and one (11.1%) patient presented with repeated falls.
The mean age (SD) at presentation to hospital was 7.38 (1.98) years in group I 
and 11.78 (1.48) years in group II. There was significant lag period between the 
first symptom noticed by the parents to the time of evaluation and diagnosis in 
all the groups. This delay in diagnosis has been reported even in other studies. 71, 
72 Reported mean diagnostic delay usually varies between 2 and 3 yrs (range 0 to 
6  yrs).  In  a  retrospective  study  of  patients  with  DMD referred  initially  for 
orthopedic consultation because of clumsiness, the first referral took place at 
age 3 years but the correct diagnosis of DMD was not made on average until 2 
years later.14 In a study by Gulati et al (2005), this difference was 2.6 yrs (mean 
age at onset - 4.8 years and at presentation - 7.4 years) 69 and 3 years, 6 months 
in another study by Thong et al (2005).71 Although developmental delay and 
other early symptoms are often noted before 5 yrs of age, they are often taken 
lightly both by the parents as well as the attending physician, except in some 
cases  with  family  history  of  myopathy.  This  leads  to  delay  in  initiation  of 
appropriate treatment and genetic counselling.
We studied various disease related milestones at various time intervals during 
course of the illness and compared it with other studies. In our study difficulty 
to get up from squatting position and inability to run were present in most of the 
patients (98.3%).  In group I, the mean age (SD) of appearance of difficulty in 
squatting and getting up was at 4.25 (1.54) years, inability to run and keep pace 
with peers as other peers at 4.1(1.64) years, abnormal gait or stance and features 
of  waddling  at  6.41(1.58)  years,  toe  walking  at  4.71(1.60)  years,  calf 
enlargement at 6 years and repeated falls form 6.16(1.45) years. In a similar 
study, use of Gower’s manoeuvre to get up was seen at 5 years, waddling at 6 
years.68 In another study by Gulati et al (2005) the commonest symptoms were 
difficult  to  run  (56.6%),  followed  by  difficulty  in  getting  up  from  floor 
(16.6%).69 
In group I a (natural history group), Inability to walk without support was seen 
at mean age of 7.67(1.3) years in 9(22.5%) patients. Of them 8 (20%) patients 
were  confined  to  wheelchair  at  a  mean  age  of  8.63(1.30)  years.  In  similar 
studies  of  Duchenne’s  muscular  dystrophy,  the age at  confinement  to  wheel 
chair in nontreated patients was, 9.21(1.48) years (King et al 2007), 50 9.5 years 
(range 6 -12 years, Anthonie et al, Dutch survey).72 9.9(0.3) years (De Silva et 
al, 1987)75 and 11(0.67) years (Pradhan et al, 2006).76  On comparison, loss of 
ambulation in our study (in natural  history group) was similar to that in the 
studies by King et al and Anthonie et al. Loss of ambulation was at a later age in 
the study by Pradhan et al (11 years), which could be due to the addition of 
some cases of Outlier’s in the study group as the upper limit for the age of onset 
was 7 years for inclusion in the study, whereas it was 5 years for classifying as 
DMD in our study.  
5(31.25%) patients in group I b, 1 each in group II and I c could not walk 
without support at entry or during the study period. Of them 2 in group I b, one 
each in group I c and II became confined to wheel chair during the study period. 
2 (22.22%) patients in group II (BMD/outlier’s) were noted to have dyspnoea 
on exertion at mean age of 10.50 years and 1 (1.7%) patient in group I a had 
dyspnoea on exertion from 7 years of age. This is in accordance with literature 
that  BMD  patients  who  are  relatively  more  active  tend  to  have  cardiac 
manifestations whereas DMD patients do not do so due to restricted physical 
activity by the end of first decade. In a study by Gulati et al (2005, 30 patients, 
mean age 10.1 years),  symptoms or  signs suggestive  of  cardiac  dysfunction 
were seen in only 3(10%) patients.69 
School performance was poor in 7 (11.7%) patients and good in 22 (36.7%) 
patients  of  group I  of  our  study.  In  a  similar  study (Thong et  al,  2005,  21 
patients  of  DMD),  7(33.33%)  had  learning  difficulties,  9(42.85%)  had 
satisfactory school performance and 4(19.04%) had dropped out of school due 
to  unknown  reasons.71This  difference  could  be  due  to  different  ethnic 
background and environment factors among the two groups. 3(5%) patients of 
DMD  had  features  of  attention  deficit  hyperactivity  disorder  requiring 
psychiatric assessment and therapy. In a study of DMD patients, ADHD was 
seen in 11.7% patients compared to 7 % in general population.31 In our study it 
appeared in the range for general population. 
Family history was present in 23.33 % of the DMD patients in our study.  In 
other studies family history was positive in one third of patients (Gulati et al, 
2005)69, 18.5% patients (Ahuja et al, 2000)70 and 23.8% (Thong et al 2005).71 
We had one family with many members affected (patient - cousins - maternal 
uncles), but the patients were evaluated only when they were symptomatic. This 
stresses that despite years of experience and availability of good screening tools, 
the  screening  tools  are  still  underutilized  stressing  on  need  for  educating 
primary care physician about the disease. 
Weakness was seen in cranial, axial and limb muscles, more in the proximal 
muscles.  Facial  weakness was common in Duchenne’s  phenotypes (group I) 
(68.33%)  compared  to  group  II  (44.44%).  With  disease  progression  facial 
weakness worsened.  This has not been commonly reported in literature. In the 
limbs,  pelvi-femoral  group  was  more  affected  than  the  other  groups;  in 
39(56.25%) patients quadriceps was equally weak and of them 13(18.84%) had 
power less than that in iliopsoas. As the disease progressed, tibialis anterior, 
proximal  upper  limbs  and  later  distal  muscles  were  involved.  Axial  muscle 
weakness was common/ severe in the DMD group compared to BMD/ Outliers. 
Axial weakness was seen in early stages, worsening with decline in limb power 
and functional grades. Presence of higher grades of facial and axial weakness 
co-related with higher GSCS grades, which was stastically significant.   
There was gradual decline in the MRC scores over years, with rapid decline in 
the later part of the first decade and just before the time of loss of ambulation. 
This is  evident  from the distribution of the MRC scores over years  and the 
corresponding figures. 
GSCS grades also correlated with the decline in MRC scores over years, but the 
functional ability appeared to better preserved at even lower MRC scores. On 
comparing  the  functional  grades  of  walking  with  power  in  iliopsoas  and 
quadriceps, patients lost ambulation only when power was less than 2 in these 
muscles. In similar study by Parreira et al (2007), there was co-relation between 
the decline in MRC scores and in the Hammersmith motor disability score test, 
which was proportional.73 In our study, there was decline in the muscle power 
but  functional  status  appeared  to  be  relatively  preserved.   This  relative 
preservation  of  functional  status  could  be  because  of  the  compensatory 
measures acquired over time by these patients. 
Skeletal  deformities  were  seen  in  66  patients,  increased  lumbar  lardosis  in 
53(76.8%), scoliosis in 6 (8.7%) and both in 7 (10.1%) patients.  23(33.33%) 
patients had wide based stance. Scoliosis was present in patients with advanced 
disease.  Of the 6 patients with scoliosis, 4(66.67%) patients had GSCS > 21 at 
presentation. 
Contractures  were  commonly  seen  at  ankle  in  56(81.16%),  at  knee  joint  in 
12(17.39%) patients, at hip joints in 8(11.39%) and at elbow joint in 1(1.4%) 
patient. There was progressive increase in the degree of ankle contracture with 
disease duration. Ankle contracture appeared first of all the joint contractures 
followed by knee, hip and later upper limb joint involvement. There appeared to 
be a period during which patients have milder  degrees (≤ 10 - 15) of ankle 
contracture and are ambulant. As the disease advances, the weakness worsens 
beyond the levels of compensation, and patients’ progressively lose ambulation 
and  have  rapid  increase  in  contractures  as  they  become  bed  bound.  On 
comparison of the ankle contractures in patients in group I a and I b, degree of 
contracture and progression was more in group I b.  There appeared to be a 
favorable degree of ankle contracture in patients who are ambulant with good 
MRC  scores  during  the  course  of  illness  which  helps  in  ambulation  as  a 
compensatory measure for a longer period of time.  
Creatine phosphokinase levels were raised more than 50 times normal in most 
patients, especially in the early stages. With progression of disease, the CPK 
levels decline. There can be low Sr CPK values < 1000 - 2000 as seen in three 
of our patients in advanced disease stage. So, low Sr CPK does not rule out 
Duchenne’s  muscular  dystrophy,  especially  in  patients  who  present  at  an 
advanced stage of illness.  
EMG was  available  for  analysis  in  49  (71.01%)  patients,  CMAP’s  were  of 
normal  amplitude  in  25(51.02%)  patients,  reduced  in  both  upper  and  lower 
limbs in 11(22.45%) patients, reduced in lower limbs in 9(18.37%) patients and 
reduced in upper limbs in 4(8.16%) patients.  Positive sharp waves were seen in 
4 (8.16%) patients and positive sharp waves with fibrillations in one (2.04%) 
patient. Interference pattern was myopathic in all the 49 patients.  
ECG changes were common in our study.  In the 30 patients with Duchenne’s 
phenotypes  (group  I),  prominent  R  wave  was  seen  in  V1  (>  4  mm)  in  29 
(96.66%) patients, R > S in V1 in 19 (63.33%) patients and R > S in V2 in 21 
(71%) patients.  Sinus tachycardia was seen in 15(50%) patients.  Among the 
ambulant and nonambulant groups, R>S in V1 was common in nonambulant 
patients (71.42% v/s 60.86%).  In a study by Ahuja et al (2000, 27 patients, 
mean age 9.7 years) sinus tachycardia was seen in 62.9% patients, R>S in V1 in 
44.4% patients. In a study by Gulati et al (2005, 30 patients, mean age 10.1 
years) R>S in V1 was seen in 76.6% and 30% had Q waves in lateral leads. 69, 70 
Prominent Q waves in lateral leads were not seen in our patients. 
In  Becker’s  phenotypes  (group  II,  5  patients),  one  (20%)  showed  sinus 
tachycardia, all 5(100%) had R wave in V1 > 4mm, 3(60%) patients had R > S 
in V1 and 4(80%) patients had R > S in V2. These changes suggest involvement 
of the posterior basal myocardium in these patients.
 In our study, Echocardiogram parameters of Duchenne phenotypes (group I) 
including  ejection  fraction,  left  ventricular  end  systolic  and  end  diastolic 
volumes and end diastolic diameter were normal, with no differences between 
ambulant  and nonambulant  groups.  In  Becker’s  phenotypes,  one patient  had 
increase in left  ventricular volumes and diameter,  with other patients having 
normal  values.  In a similar  study by Ahuja et  al  (2000,  study group having 
14.8% nonambulant patients and mean age of 9.72 years) there was no evidence 
of  any  cardiac  dysfunction  on echocardiogram in  any of  the  patients.  In  an 
another study by Gulati et al (study group having 63.3% nonambulant patients 
and mean age  of  10.1 years)  mean ejection fraction  was  <  50% in 17.8  % 
patients and mean was 52.5% (SD - 6.3).69, 70 Our study group was similar to that 
of Ahuja et al, as 57.7% of the our patients were ambulant and mean age of our 
patients when echocardiogram was done was less than 7.7 years.  Absence of 
echo abnormalities in our patients may be due to younger age of our DMD 
patients.  Over all  cardiac symptoms are less common in younger DMD, but 
ECG abnormalities are more frequent than echocardiogram abnormalities. 
Muscle biopsies showed myopathic features, fibrosis, adipose tissue infiltration, 
inflammatory infiltrates and absent dystrophin staining. Absence of dystrophin 
2, 3 was the commonest pattern noted. 
Diagnostic testing can also be done with gene based tests or western blot tests. 
4(5.8%)  of  our  patients  with  biopsy  suggestive  of  Dystrophinopathy  had 
negative test when analyzed for deletions in dystrophin gene before biopsy was 
done.  
Of the 69 patients, 54(78.26%) were on treatment, 46(66.67%) on deflazacort, 
and 8(11.59%) on Prednisolone. All patients were on physiotherapy including 
stretching exercises.
The mean age at starting steroids was 6.69 years in group I a, 7.23 years in 
group I b and 7.23 years in group I c. The mean dose was 0.96 mg per kg for 
deflazacort and 1 mg per kg for Prednisolone given on alternate days.  
When  treatment  was  started,  2(2.9%)  of  our  patients  were  3  years  of  age, 
1(1.4%) was 4 years and 4(6.9%) were 5 years of age. Others were more than 5 
years of age at the time of starting steroids.  In our patients in group I b, the 
mean age at starting steroids was 6.69 years. In a study by Merlini et al (2003) 
on early treatment with Prednisolone in younger DMD patients (range 2.4 to 4 
years), there was beneficial effect (delaying the time to loss of ability for rising 
from the floor).74 Most of our non treated patients, who lost ambulation, did so 
before 10 years of age. Of the 7 patients more than 10 years in group I b (treated 
group), 6 patients continued to walk even after 10 years of age. There are no 
guidelines for optimal age of starting steroids in DMD patients. 44, 45The study by 
Merlini et al and our study show that early use of steroids can be beneficial in 
DMD. 
At entry into study the mean age was 7.88 v/s 9.56, mean cumulative MRC 
score was 12.93 v/s 13.2 and mean cumulative GSCS was 15.72 v/s 14.69 in 
group I a (untreated) and group I b (treated) respectively. Stastically there was 
no significant differences in the mean MRC and GSCS scores but the age to 
achieve same MRC and GCSC scores was significantly less in treated group 
than in untreated group (p = 0.011) i.e. treated patients tended to have higher 
grade of GSCS and lower MRC scores for the corresponding age. 
There was significant decrease in the frequency of falls after starting treatment.  
There was a significant difference in the age to reach stage of inability to walk 
without support (7.67 v/s 9.60) and wheel chair bound stage (8.63 v/s 11.50) in 
the two groups, with treated one remaining ambulant for longer time.  
6(37.5%) of  the 16 patients  in  group I  b  were ambulant  after  10 years  age 
compared to 2(5%) of the 40 patients in group I a. 7(17.5%) patients in group I 
a were confined to wheel chair before 10 years of age, where as in group I b all 
patients below 10 years were ambulant till follow up, with two (12.5%) patients 
being ambulant  with support.   In a  similar  study (  De Silva et  al,  1987) of 
Prednisolone  in Duchenne muscular dystrophy, mean age at confinement to 
wheel chair was 9.9(0.3) years in the control group and 12.2(0.5) years in the 
treated group, 13.1(0.5) years in the group treated for more than 2 years. Of the 
20 patients in treated group 4(20%) were confined to wheel  chair before 10 
years of age compared to 12 of the 22(54.54%) patients in the control group 
who were confined to wheel chair.75  In another study (Pradhan et al, 2006), 44 
patients were started on 0.75 mg/ kg /  day of Prednisolone.  15 patients had 
follow up for > 2 years. Prednisolone treated patients became wheel chair bound 
at the mean age of years 14.08(.75) years compared to 11(.67) years in controls 
(22 patients), with a gain of about 3 years in terms of independent walking. 76 In 
another study (King et al, 2007, 143 patients, 75 in treatment group), the mean 
age  at  loss  of  ambulation  was  9.21(1.48)  years  in  non  treated  group  and 
12.52(3.02)  years  in  treated  group,  with  a  gain  of  3.3years  of  independent 
ambulation.50  Our study results were similar to that in study by De Silva et al 
and King et al with gain of 3 years of ambulation or differences in the age at 
confinement to wheel chair. Patients in the other study by Pradhan et al lost 
ambulation at later date, which could be explained by the upper limit of age at 
symptom onset of 7 years in this study, compared to 5 years in our study. Some 
patients with Outlier/BMD phenotypes may have been include in this study.        
Over all there was role of steroids in decreasing the progression and prolonging 
ambulation in DMD patients, as more number of a given age group patients on 
treatment  were  ambulant  compared  to  those  who  had  not  received  therapy. 
There  was  difference  between  performance  on  functional  tests  ability  and 
muscle power. An increase in muscle force due to steroids has been reported in 
earlier  studies,  which  was  not  seen  in  our  study,  but  the  decline  was 
significantly slower in the treated group.  Thus medical therapy and physical 
therapy in the form of structured approach individualized for each patient can 
help prolong ambulation and improve quality of life.  
Body weight had increased in our patients on steroids but  none qualified as 
obese.  One of  the patient  required  reduction of  Prednisolone  dosage  due  to 
weight  gain,  but  none of the patients  required withdrawal of  therapy due to 
weight gain.  Weight gain is reported in up to 75-80% of the patients on steroid 
therapy.13 In a similar study by Pradhan et al (2005), of the 44 patients initiated 
on  steroid  therapy,  14  required  withdrawal  of  therapy  due  obesity  and 
cushingoid features.76   
There  was  decrease  in  the  rate  of  increase  in  height  after  starting  steroids. 
8(50%) patients were below the 50 the percentile for age matched values at the 
time of starting steroids. When they were evaluated during study period (when 
they were on steroids for more than 2 years), 16(100%) patients were below the 
50th percentile and out of these 8(50%) were below the 10th percentile for the 
corresponding age matched values. 
One (1.4%) patient had osteoporosis related fracture.  Long bone fractures as a 
result of falls are common, affecting 20.9% of patients (Mc Donald et al, 2002), 
half of them losing ambulation as a result. 77  Fractures rates were lower in our 
study and were also not described in the study by Pradhan et al, where as they 
occurred at higher rates in other studies. These differences may be due to ethnic 
differences, differences in the climate and associated exposure to sunlight and 
calcium/ vitamin D supplementation which was given in both our study and the 
study by Pradhan et al, along with steroids. Cataracts were not observed in our 
study groups.
All our patients were told about the possibility of weight gain and decrease in 
height related to steroid therapy and dietary measures. Calcium supplementation 
were given to all the patients from the time of initiation of steroids, this may the 
reason for lower incidence of fractures in our patients.  Various studies have 
reported  on  the  steroid  related  complications,  so  appropriate  dietary  advice, 
vitamin D and calcium supplementation, prevention of falls, regular assessment 
for cataracts are important to prevent steroid related complications.  
Our  patients  did  not  have  regular  bone  densitometry  and  spinal  curvature 
assessment based on spine x rays. These two were the limitations of our study. 
                                                   Conclusions 
• In our Neuromuscular Clinic, Dystrophinopathies form the commonest of 
muscle   disorders;   they   constituted   about   45% of   the   primary  muscles 
diseases. 
• There  is  progressive  decline  in  the  muscle  power  and  also  functional 
ability. Without therapy patients become wheel chair bound by age of 8 to 
9 years. Steroid therapy helps to maintain/ slow the decline and prolong 
duration of ambulation by another 2 to 3 years. 
• Most of our patients had facial weakness and significant axial weakness 
even in the initial stages, which worsened with disease progression. This 
progression of axial and facial weakness may indicate late stage of disease 
with impeding loss of ambulation. Facial weakness and axial weakness 
has not been hitherto been reported in Dystrophinopathies. 
• Quadriceps  was  involved  early  in  many  patients,  being  as  weak  as 
iliopsoas in 56.25% patients and weaker than iliopsoas in 18% patients. 
• Changes  in  muscle  force  and  functional  ability  progresses  at  different 
rates.  Functional changes are more helpful to assess disease progression 
and to evaluate the effects of therapy in ambulant DMD patients. 
• Contractures  occur  as  a  compensatory  measure,  initially  they  help  in 
ambulation,  but  as  weakness  progresses,  and  any  further  increase  in 
contractures  will  hamper  ambulation.  Ankle  contractures  below  20 
degrees  are  common  in  ambulant  patients  and  greater  degrees  of 
contractures are seen in nonambulant patients.
• While on therapy there can be steroid related weight gain, stunted growth 
and  osteoporosis  which  is  important  as  increase  in  weight  can  impair 
ambulation and falls may lead to fractures in weak bones, so weight gain 
and bone density has to be monitored. 
• In our study, there was lower incidence of fractures, may be due racial 
differences  and  early  supplementation  with  vitamin  D/  calcium  with 
education about fractures/ falls. 
• Multidisciplinary  approach,  through  a  specialized  clinic  with  members 
from all  concerned  specialities,  involving early  diagnosis,  medical  and 
physical  therapy,  genetic  counselling,  with  supportive  care  in  the  late 
stages improve quality of life in Duchenne Muscular dystrophy patients. 
Such an approach can address all the aspects of the disease process and 
provide  an  individualized  care  for  each  patient,  according  to  their 
requirements.
Structured approach for management of Duchenne muscular dystrophy
          DMD is progressive illness with significant morbidity and mortality. 
There are various phases in the natural history of the illness, which may be 
different in individuals. Due to the progressive nature and different phases, 
therapeutic measures need to be structured to benefit each phase of illness 
and each individual.  These measures should address medical, rehabilitative, 
genetic  and  psychosocial  aspects  and  terminal  care  issues  related  to  the 
illness. 
Structured  approach  involves  multidisciplinary  management,  involving 
neurologist, physicians from physical and medical rehabilitation and medical 
genetic department, physiotherapist, occupational therapist and social worker.
It should ideally begin from antenatal period or neonatal period and continue 
as the patient’s disease evolves over time. 
Early symptomatic stage (usually < 5 years)
 
During this period, boys have early feature like inability to run and climb 
stairs, squat and get up, gait abnormalities. 
There are few studies on early initiation of steroids in DMD, but considering 
the  biopsy  findings  of  inflammation  in  early  stages,  beneficial  role  of 
steroids,  there  appears  to be role  for  steroids in this  period,  with vigilant 
observation for complications related to steroid therapy. 
Boys  should  be  initiated  on  daily  strength  and  flexibility  exercises,  and 
stretching  exercises.  Education  about  disease  course,  physical  activity, 
prevention of falls and dietary intake should be given.  
Symptomatic phase – intermediate (usually 5 years to 8 years) 
During  this  period,  boys  show  features  of  muscle  weakness,  falls  and 
contractures,  in  addition  various  compensatory  measures  like  ankle 
dorsiflexion, increasing lumbar lardosis and widened stance, which help in 
ambulation and to maintain the base of support under the centre of mass of 
the  body.  During  this  period  boys  should  have  steroids,  regular 
physiotherapy,  Achilles  tendon  stretching  exercises  to  prevent  severe 
contraction which may impair balance and ambulation and dietary advice to 
prevent  weight  gain.   AFO’s  should  not  be  used  for  ambulation  because 
fixing the ankle at 90 degrees impairs balance and diminishes the walking 
ability.  When plantar flexion is more than 20 degrees, only then patient may 
have balance problems, so contractures less than 20 degrees should not be 
corrected/ treated surgically as it helps maintain knee extension during stance 
phase.   During  this  period  patients  should  be  advised  about  falls  and 
increased  risk  of  fractures  due  to  steroid  therapy  related  oteopenia.  They 
require  calcium  supplementation  and  screening  with  DEXA  annually.  If 
fractures occur, appropriate treatment to be done so that early mobilization is 
achieved,  to  prevent  loss  of  ambulation,  worsening  of  weakness  and 
contractures due to non ambulation. Occupational therapy should be given to 
help in daily activities with assistance. DMD patients have IQ scores one SD 
below the normal, with more impairment of verbal memory and expressive 
language. They may require special education, oriented to cope with these 
deficits.   Behavioral  changes  related  to  disease  and steroid  therapy to  be 
monitored.  During  this  period  there  is  progressive  decline  in  respiratory 
functions, so patients should be monitored and advised regarding breathing 
exercises with incentive spirometer.
Symptomatic phase – late (usually 8 years to 12-14 years) 
With  progression  in  weakness,  compensatory  mechanism  become  less 
effective,  gait  becomes  more  abnormal.  With  severe  quadriceps  weakness 
they cannot walk and once knee flexion contracture  develops they cannot 
stand. Stretching exercises should be continued and orthotics may be used to 
maintain ability to stand. At this stage, patients should have wheelchair to 
maintain  independent  mobility  and  conserve  energy.  During  this  phase 
scoliosis develops and worsens, so patients should be regularly screened with 
spine x rays every 6 months from about 10 years of age, wheel chair should 
have an appropriate pressure distributing seat cushion, and proper head lateral 
trunk  supports.  Patients  should  have  cardiac  and  respiratory  evaluation, 
which should be repeated annually. Steroids and calcium supplements should 
be continued with dietary advice.
    
    Symptomatic phase – dependant/ terminal (Usually 14 years and above) 
During  this  period spinal  deformity  (scoliosis)  continues  to  worsen, 
respiratory and cardiac complications appear. When scoliosis is of sufficient 
degrees,  (usually  20  -  30  degrees)  to  impair  seating  and  respiration, 
correction should be done.  Early surgery may be helpful as scoliosis in DMD 
is progressive, with progression paraspinal muscles are replaced by fibro fatty 
tissue making, surgical dissection difficult, and with increasing age there is 
decrease in forced vital capacity.  (With FVC < 35% patients are at high risk 
for  pulmonary  complications).  Preoperatively,  all  patients  should  have  a 
cardiac and pulmonary function assessment.  Release of other contractures to 
help seating should be considered.  Patients should be continued on steroids 
(as it may help to maintain respiratory functions, respiratory exercises and 
supportive  measures).  When  they  have  pulmonary  insufficiency  assisted 
ventilation at night with nasal masks with end expiratory pressure (bi-level 
positive airway pressure) may help.  With further worsening they may require 
continuous  ventilator  support.   Cardiac  functions  may  decompensate  and 
require therapy with ACE inhibitors and Beta blockers. Patients at this stage 
have difficulties in essentially all activities of daily living skills, including 
transferring, feeding, and dressing, thus requiring full time assistance. 
Psychosocial support is essential at each stage to help cope with the chronic 
illness. 
Assessment of presymptomatic cases
In families with history of DMD, diagnosis can be established early in the 
antenatal  period with fetal  muscle  biopsy and after  birth by screening for 
serum CPK.  In those without family history, diagnosis is usually delayed till 
patients  gross  features.  DMD  boys  usually  have  delayed  milestones, 
abnormal gait  and running which if evaluated can help in early diagnosis. 
This would require education about the early manifestation of the disease 
among general population and primary care physicians.  Genetic counselling 
to  be  considered  to  help  parents  in  planning  further  pregnancies  and 
screening other siblings and individuals at risk. 
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                                                                         APPENDICES -1
             PROFORMA FOR ANALYSIS OF DUCHENNE MUSCULAR DYSTROPHY 
             Name:                                                 Age (yrs):                   Hospital no:   
Age at presentation to hospital:         Age at entry into study:
Age at first symptom onset:
First complaint noticed and age:
• Delayed milestones
• Waddling gait
• Toe walking
• Cannot squat and get up without 
support
• Cannot run
• Cannot climb stairs
• Repeated falls
• Fatigue
• Cramps/pain in legs
• Calf enlargement
• Foot abnormality
• Spinal deformity
• Dyspnoea on exertion
• Sibling of DMD patient
• Learning difficulties
• Others
Milestones: (by years)
• Walking without support
• Running
• Calf enlargement 
• Toe walking
• Uses Gower’s
• Waddling gait
• Cannot run
• Cannot climb stairs without 
support
• Repeated falls
• Cannot walk without support
• Cannot stand without support
• Wheel chair/Bed bound
• Dyspnoea at: exertion            : 
rest
• Spinal deformity
Behavioural changes: Hyperactivity / autistic features/others
School performance: Good / average / poor
Family history: Consanguinity/ affected sib’s/ affected uncle/ others
Functional scoring:               Start      6 months      12 months      18 months
• Squatting/getting up
• Walking
• Getting up from chair
• Climbing stairs
• Falls / day
• ADL’s 
Contractures: (deg)      first visit      start      6 months    12 months   18 months
• Ankle
• Knee
• Hip
• Iliotibial band
Hypertrophy:  Calf / deltoid / brachioradialis / quadriceps / hamstrings / triceps 
/ glutei
Muscle strength           first visit   start     6 months   12 months  18 months
• Neck flexors
• Facial muscles
• Bulbar muscles
• Deltoid
• Biceps
• Iliopsoas
• Gluteus maximus
• Knee ext
• Tib anterior                          
 Spinal deformity: Scoliosis / kyphosciolosis                         
                             First visit          Start             6 months              12 months 
18 months
Height (cms)
Weight (kgs)
Sr CPK         First visit       start        6 months         12 months    18 months    
ECG:
• HR                                                               R - V1 > 4 mm 
• R/S – V1                                                       R/S – V2
• Blocks                                                          Arrythmia’s
• RVH                                                             BVH 
ECHO:
 EF                                                                 LVESV
 LVEDV                                                        LVEDD
 Wall motion abnormalities
BIOPSY: 
• Myopathic features: 
• Fibrosis: endomysial/ perimysial/ both/ absent
• Fibrosis grade:  focal/mild/ moderate/ extensive
• Adipose tissue: interfasciular/ intrafascicular/ both/ absent
• Adipose tissue: focal/mild/ moderate/ extensive
• Inflammation: perivascular/ endomysial/ both/ absent/ nodular 
aggregates/ granulomas
• Inflammation: focal/mild/ moderate/ extensive
• Dystrophin absent:  1 /  2  /  3  /  1,2  /  1,2,3  / 2,3
• Dystrophin weak:  1 /  2  /  3  /  1,2  /  1,2,3  / 2,3
• Revertant fibres: absent/ occasional/ few/ many
• Sarcoglycan staining:    Alpha - present/ absent/ weak         Beta - present/ 
absent/ weak
                                        Delta - present/ absent/ weak          Gamma - 
present/ absent/ weak
• Merosin staining: present/ absent
• Calpain staining: present/absent/ reduced
• Dysferlin staining: present/ absent/ reduced. 
Medications:
• Started at age (yrs) 
• Dose
• Complications: Decreased growth / weight gain / fractures / hirusitism.
Overall performance: better/ good / same / worse

